



NATIONAL HEALTH LABORATORY SERVICE

National Cancer Registry



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

EKURHULENI POPULATION- BASED CANCER REGISTRY 2018 ANNUAL REPORT

Johannesburg, South Africa, March 2020



Copyright © 2020

Citation:

**National Cancer Registry, South Africa. Ekurhuleni Population-Based Cancer Registry
Annual 2018 Report. www.ncr.ac.za.**

Sponsors for publication:

Compiled by:

Dr. Elvira Singh (Head of Department)

Ms. Lactatia Motsuku (Epidemiologist)

Mrs. Lerato Khoali (Surveillance Manager)

Dr. Mazvita Sengayi-Muchengeti (Senior Epidemiologist)

Mr. Wenlong Chen (Medical Scientist)

Ms Natasha Abraham (Epidemiologist)

Ekurhuleni Cancer Registry

National Cancer Registry, National Health Laboratory Service

1 Modderfontein Road, Sandringham

Johannesburg

South Africa

2131

Tel: +27 11 386 0548

Fax to email: +27 11 386 6516

Website: www.ncr.ac.za

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	v
LIST OF TABLES	vi
LIST OF FIGURES	vi
ACRONYMS AND ABBREVIATIONS	vii
EXECUTIVE SUMMARY	viii
INTRODUCTION	1
BACKGROUND	2
METHODS	3
Data Sources	4
Data Collection and Processes	7
Confidentiality	9
Statistical Methods.....	10
RESULTS	11
Overall Cancer Incidence.....	11
Results of Selected Cancers	19
Childhood cancers incidence	21
Quality.....	21
DISCUSSION	24
REFERENCES	26
APPENDICES	27
Apendix 1: List of Data Sources	27
Apendix 2: South African Cancer Notification Form.....	28
Appendix 3: Tables of Incidence by site, sex, age group and population group Ekurhuleni 2018.....	29

ACKNOWLEDGEMENTS

This work has been possible through a full grant provided by the South African Medical Research Council.

The National Cancer Registry (NCR) would also like to thank all individuals, organisations and relevant stakeholders that played a critical role in the operations of Ekurhuleni Population-Based Cancer Registry.

African Cancer Registry Network (AFCRN)	Lancet Laboratories
Ampath Laboratories	National Health Laboratory Services
Arebaoke Hospice	National Institute for Communicable Diseases
Benoni Oncology Centre	Pathcare Laboratories
Chris Hani Baragwanath Academic Hospital	Pholosong Regional Hospital
Charlotte Maxeke Academic Hospital	South African Oncology Consortium (SAOC)
Department of Health, South Africa	South African Paediatric Oncology Network
Drs Gritzman & Thatcher Inc Laboratories	St Francis Hospice
Eastrand Benoni Hospice	Stepping Stone Hospice
Edenvale Regional Hospital	Steve Biko Academic Hospital
Far East Regional Hospital	Tambo Memorial Regional Hospital
Gauteng Oncology Alberton Private Hospital	Tembisa Regional Hospital
Gauteng Oncology Prostate-Clinic	Thelle Mogoerane Regional Hospital
Gauteng Oncology Linmed Private Hospital	Union for International Cancer Control (UICC)
International Agency for Research on Cancer (IARC)	Vermaak Laboratories
International Association of Cancer Registries (IACR)	World Health Organization (WHO)
	South African Medical Research Council (SAMRC)

LIST OF TABLES

Table 1: Summary statistics for all cancers in Men, Ekurhuleni (2018)	13
Table 2: Summary statistics for all cancers in Women, Ekurhuleni (2018)	14
Table 3: Childhood cancers	21
Table 4: Percentage of cases Morphologically Verified, diagnosed clinically or diagnosed by Death Certificate Only	22

LIST OF FIGURES

Figure 1: Ekurhuleni Metropolitan Municipality map	2
Figure 2: Population of Ekurhuleni Metropolitan Municipality in 2016	3
Figure 3: Ekurhuleni Population-Based Cancer Registry data sources map	6
Figure 4: Ekurhuleni Population-Based Cancer Registry data flow diagram	7
Figure 5: Percentage of cancer cases by gender and race	11
Figure 6: Frequency of most common cancers in males	16
Figure 7: Age Standardised Incidence Rates for common cancers in males	16
Figure 8: Frequency of top 10 common cancers in females	17
Figure 9: Age standardised incidence rates for the common cancers in females	17
Figure 10: ASR of common cancers in men by population group	18
Figure 11: ASR of common cancers in women by population group	18

ACRONYMS AND ABBREVIATIONS

AFCRN	: African Cancer Registry Network
DoH	: Department of Health, South Africa
DoHA	: Department of Home Affairs, South Africa
EPBCR	: Ekurhuleni Population-Based Cancer Registry
IACR	: International Association of Cancer Registries
IARC	: International Agency for Research on Cancer
ICCC	: International Classification of Childhood Cancer
ICDO-3	: International Classification of Diseases for Oncology Third Edition
NCR	: National Cancer Registry, South Africa
POPI Act	: Protection of Personal Information Act, South Africa
SA	: South Africa
SAMRC	: South African Medical Research Council
SAOC	: South African Oncology Consortium
STATSSA	: Statistics, South Africa
UICC	: Union for International Cancer Control
WHO	: World Health Organization
ASR	: Age-Standardised Incidence Rate
WSP	: World Standard Population

EXECUTIVE SUMMARY

The systematic collection, storage, analysis, interpretation and reporting of cancer cases known as cancer surveillance, is the responsibility of the National Cancer Registry in South Africa. In 2011, the South African Department of Health enacted Regulation No 380 of the National Health Act (Act 61 of 2003), which formally established the National Cancer Registry (NCR) as its delegated agency for the collection of cancer surveillance information and made cancer a reportable disease. It also mandated the NCR to establish Population-Based Cancer Registries for the country. The Ekurhuleni Population-Based Cancer Registry (EPBCR) was thus established in Gauteng, as the first urban population-based cancer surveillance site for the country. This is the second cancer incidence report for the Ekurhuleni District accounting for all cancers diagnosed in 2018, the second year of complete data collection in the EPBCR.

A total of 4695 new cancer cases were registered for 2018 with 52% of cases being female. The majority of cases were diagnosed in the White population (52%), followed by 46% in the Black population. The common cancers amongst males (ranked by age-standardised incidence rates) were prostate, colorectal, lung, melanoma and oesophageal cancers. The top five cancers amongst women were breast, cervical, colorectal, uterine and lung cancers. The morphological verification rate for the EPBCR was over 95%. Only nine cancers were reported with age unknown. There were 235 cases of cancer (5%) reported where the primary site was unspecified or uncertain.

The combined information provided by the EPBCR and the national pathology-based cancer registry provide an important snapshot of the cancer landscape in South Africa. It is reassuring that the leading cancers in the two registries are similar providing reliable information for policy making and healthcare interventions for the country. In the coming year, the EPBCR will focus on a detailed evaluation of the completeness, timeliness, comparability and validity

of the registry, enhancement of case finding and implementation of the ongoing QA/QC plan. Together with its partners and stakeholders the EPBCR aims to become the preeminent source of cancer statistics for the country and an example of excellence for population-based cancer registries on the continent.

INTRODUCTION

In South Africa, the systematic collection, storage, analysis, interpretation and reporting of cancer cases (1), known as cancer surveillance, is the responsibility of the National Cancer Registry (2,3). Through the operation of a pathology-based cancer registry, a population-based cancer registry and its research initiatives, the NCR enumerates cancer cases, calculates cancer incidence for the country and describes cancer risk factors relevant to the local population. (2).

In 2011, the South African Department of Health enacted Regulation No 380 of the National Health Act (Act 61 of 2003), which formally established the National Cancer Registry (NCR) as its delegated agency for the collection of cancer surveillance information (3). This regulation made cancer a reportable disease with every health-care worker obliged to report confirmed cancers to the NCR (3,4). In addition, it mandated the NCR to establish Population-Based Cancer Registration for the country. After consultation with local and international cancer surveillance experts it was decided that an estimated minimum of four population-based cancer registries will be needed to confidently extrapolate national cancer incidence. The Ekurhuleni Population-Based Cancer Registry (EPBCR) was thus established in Gauteng, as the first urban population-based cancer surveillance site for the country.

The Ekurhuleni Metropolitan District is an ethnically and socioeconomically diverse urban community (5). The name Ekurhuleni means ‘place of peace’ in Tsonga, and the municipality is one of three metropolitan municipalities within the Gauteng Province (6). Ekurhuleni is highly urbanized, with 99.4% of the population living in urban settlements ranging from informal settlements to elite urban residential suburbs (6). As of March 2020, the Ekurhuleni Population-Based Cancer Registry has eight surveillance officers that actively collect cancer data of Ekurhuleni residents from regional and tertiary public hospitals, private healthcare

facilities and hospices. Data collection from healthcare facilities and other reporting sources began in January 2017. This is the second cancer incidence report for the Ekurhuleni District accounting for all cancers diagnosed in 2018, the second year of complete data collection in the EPBCR.

BACKGROUND

Population Covered

i. Geography

The City of Ekurhuleni Metropolitan Municipality forms the local government of the East Rand region of Gauteng, South Africa (7). Ekurhuleni Metropolitan Municipality occupies 1 975km² in the east of Gauteng province (6). Ekurhuleni consists of nine, relatively small, towns: Alberton, Benoni, Boksburg, Brakpan, Edenvale, Germiston and Kempton Park, Nigel and Springs. Of these, Kempton Park, Benoni, and Springs are the largest. It also incorporates four previously disadvantaged communities namely Tembisa, the Katorus complex, the Kwatsaduza complex, and the Daveyton Etwatwa area (6).




Figure 1: Ekurhuleni Metropolitan Municipality map

ii. Population Size and Composition

Ekurhuleni has a population of 3,379,104 persons, a population density of 1609 persons/km² and a population growth rate of 2.4% (8). Ekurhuleni represents over 6% of the population of South Africa (8). Figure 2 below shows the population pyramid of Ekurhuleni according to the 2016 Community survey (8).




Figure 2: Population of Ekurhuleni Metropolitan Municipality in 2016

METHODS

The Ekurhuleni Population-Based Cancer Registry employs cancer registration guidelines and strategies developed by the International Association of Cancer Registries (IACR), the International Agency for Research on Cancer (IARC) and the African Cancer Registry Network (AFCRN). In short, the EPBCR employs both passive and active surveillance, collecting data on all cancer patients residing in Ekurhuleni metropolitan municipality diagnosed by clinical, radiological, pathology or any other means of investigations.

Data Sources

i. Government and Private Hospitals/Healthcare Facilities

Ekurhuleni population-based cancer registry has multiple data sources. The data sources extend beyond the borders of the Ekurhuleni metropolitan municipality due to the nature of the South African healthcare referral system. The municipalities do not often have all levels of care (level 1: Primary health care clinic, Community health care centre, District hospital, level 2: Regional hospital, level 3: Provincial tertiary hospital, and level 4: Central hospital and Specialised hospital) within its borders (9). Therefore, patients may be referred out of the municipality to access further diagnosis and management. Secondly, South African patients are a highly mobile population and have the freedom to choose the healthcare facility they prefer, which is often not necessarily within the borders of the district they reside in.

In addition to the public healthcare facilities, South Africa also has a large and well-resourced private healthcare industry. Sixteen percent of the South African population has medical health insurance and is thus able to access healthcare in private healthcare facilities. Therefore, in order to obtain complete reporting from the Ekurhuleni District's population, the EPBCR also collects data from private hospitals, and clinicians in independent private practice (See Appendix 1 for a comprehensive list).

ii. Laboratories, Oncology Networks and Associations

South Africa has an expansive network of both public and private laboratories. An estimated 80% of the SA's population is serviced by NHLS, which has 268 (as of March 2019) laboratories around nine provinces of SA (10). The other estimated 20% of the population is covered by private laboratories which include but not limited to: Ampath, Pathcare and Lancet laboratories. Both public and private laboratories send electronic reports of patients diagnosed with cancer to the NCR national pathology surveillance programme. The surveillance officers use all the pathology reports received from laboratories together with other data tools (medical

files, hospital register, pharmacy list etc.) to check, identify, trace and register patients from Ekurhuleni metropolitan municipality into the EPBCR.

In addition, The South African Pediatric Oncology Group and the South African Oncology Consortium (SAOC) report their relevant data to the NCR. The surveillance officers use these data sources to consolidate missing information for patients already registered in the EPBCR database, or to trace and notify the patient in conjunction with other data tools from different data sources.

Finally, surveillance officers use hospital registers, patient files and mortuary records to identify new patients not already recorded in an existing database available to the NCR.

iii. The Hospice

Other than the hospitals, laboratories, cancer networks and associations, the surveillance officers visit hospices at regular intervals in order to consolidate information missing for patients already registered from other data sources such as hospitals, as well as to report any new patients identified.

iv. Vital Statistics (Death Registration)

The Department of Home Affairs (DoHA) is the custodian of vital statistics for SA. The Statistics South Africa (STATSSA) also has cleaned vital statistics data for South Africans that can be used to consolidate vital status (i.e. dead/alive) in the EPBCR. However, STATSSA is unable to legally share patient-level data with other official organisations. To compensate for the challenge, the surveillance officers visit the mortuaries within health facilities in order to trace and report cases of cancer for patients who may have been missed while alive.

Figure 3 below illustrates the data sources for Ekurhuleni Population-based cancer registration as of 31 December 2018.




Figure 3: Ekurhuleni Population-Based Cancer Registry data sources map

Data Collection and Processes

Figure 4 below illustrates the data flow for the EPBCR




Figure 4: Ekurhuleni Population-Based Cancer Registry data flow diagram

The EPBCR uses both active and passive methods of case finding.

Active case finding:

- The surveillance officers visit healthcare facilities to review electronic and/or physical records of patients such as patient files, admission registers, pathology reports, radiology reports, death registers, outpatient registers, pharmacy registers and clinician's statistical records in order to notify confirmed cancer cases on the cancer notification forms.

Passive case finding:

- As mentioned above, both the South African Paediatric Oncology Research Group and the South African Oncology Consortium (SAOC) passively provide data to the NCR for the Ekurhuleni district.

Inclusion criteria for both active and passive case finding methods:

- All confirmed cancer cases, in persons who are resident in the Ekurhuleni Metropolitan Municipality, diagnosed since 1st January 2018 must be reported to the registry.
- Cancer cases include:
 - Cases considered as malignant in the morphology section of the International Classification of Diseases for Oncology (ICD-O); behavior code-3 are reported to the registry.
 - Cancers in metastatic sites (for example, lymph nodes) are registered with the primary tumor site topography. If this is not known, it is registered as an unknown primary site.

The surveillance officers extract data/variables required (See Appendix 2: South African Cancer Notification Form) from data sources such as medical records, and code the cancer diagnosis according to the International Classification of Diseases for Oncology 3rd edition (ICDO-3) for topography and morphology. A pathology report, where available, is filed with the corresponding notification form. Reports are filed according to the date and facility of diagnosis.

The files are then sent to data capturers for data entry on the RedCap system. The NCR uses RedCap instead of the IARC recommended CanReg system because CanReg did not meet the current data processing requirements, such as large storage capacity, simultaneous multiple users and virtual network use.

The captured files are sent to the surveillance manager for quality assurance and quality control. The Surveillance manager uses both the physical notification forms and electronic records on Redcap for each individual cancer case to check for duplicates, completeness, and consistency. The files are stored in a locked cabinet for 20 years as per the South Africa Protection of Personal Information Act (POPI Act) before they are permanently destroyed (11).

The completed, quality assured dataset is extracted per year (1st January to 31st December for each year) for cleaning and analysis on Stata.

The analyzed data is then used for annual incidence reports, teaching/training, and research purposes.

Confidentiality

The NCR adheres to the NHLS, the IARC/IACR guidelines and the POPI Act to ensure the preservation of confidentiality during EPBCR surveillance process (11). Request to use EPBCR data by entities/individuals is sought in writing to the NCR. The statistics of cancer data are released in an aggregated format through the annual reports published on the NCR website.

Statistical Methods

The results are presented as:

- the number of new cancer cases,
- the percentage of all new cancer cases,
- Age-Standardised Incidence Rate (ASR) per 100 000 and
- Lifetime risk for 2018 (1st January 2018-31st December 2018)

The results are further stratified by:

- sex (Male and Female),
- population group (Black, White, Asian & Coloured) and
- age groups (5 year interval e.g. 0-5years, 5-10, 10-15 etc.)

For Age standardization, the Segi-World Standard Population (WSP) is used as per international cancer registration norms. STATSSA mid-year population data for Ekurhuleni metropolitan municipality is used as a denominator.

The Calculation methods are as follows:

$$\begin{aligned}\text{Crude} &= \frac{\text{Number of new cases}}{\text{Mid-year population}} \times 100,000 \\ \text{WSP weighting} &= \frac{\text{WSP (for each age group)}}{\text{Total WSP for all age groups}} \times 100,000 \\ \text{ASR} &= \text{Crude} \times \text{WSP weighting}\end{aligned}$$

RESULTS

Overall Cancer Incidence

A total of 4695 cancers were registered by the EPBCR for 2018 with 2247 cases (48%) occurring in males and 2448 (52%) occurring in females. Benign, in-situ cancers and cancers of unknown behaviour were excluded from the data collection and analysis.

Figure 1 below shows the total number of cancer cases (percentage) diagnosed in 2018 by gender and race. 52% of cases were diagnosed in the White population and 46% in the Black population.




Figure 5: Percentage of cancer cases by gender and race

Table 1 and 2 illustrate a detailed tabulation of cases registered in 2018 for males and females. The tables show the total number of cases registered, crude rates per 100 000 population, age-adjusted incidence rates per 100 000 population, and lifetime risk for each cancer. Appendix

tables further elaborate on these data by demonstrating frequency, age-standardised and age-specific incidence rates by population group and gender.

Table 1: Summary statistics for all cancers in Men, Ekurhuleni (2018)

Site	ICD10	N*	Crude Rate	ASR	Cum Risk 0-74	Lifetime risk 0-74
All sites	All	2247	137.00	140.81	15.10	7
All but C44	All but C44	1542	94.07	97.04	10.77	9
Lip	C00	6	0.37	0.36	0.04	2278
Tongue	C02	14	0.85	0.91	0.11	915
Mouth	C06	14	0.85	0.91	0.12	826
Salivary gland	C07	7	0.43	0.42	0.06	1552
Naso-Oropharynx	C11	27	1.64	1.68	0.20	501
Oesophagus	C15	65	3.96	4.28	0.53	187
Stomach	C16	27	1.64	1.67	0.19	528
Small intestine	C17	6	0.37	0.34	0.05	2158
Colorectal	C18	122	7.43	7.58	0.80	125
Anus	C21	15	0.91	0.87	0.10	960
Liver & Bile duct	C22	32	1.95	1.92	0.22	459
Pancreas	C25	28	1.70	1.76	0.22	448
Larynx	C32	16	0.97	1.04	0.15	668
Lung	C34	82	4.99	5.15	0.63	159
Bone	C41	15	0.91	0.91	0.10	1019
Melanoma	C43	73	4.44	4.56	0.46	218
SCC of skin	C44	191	11.63	11.84	1.21	83
BCC	C44	489	29.77	30.52	3.56	28
Skin other	C44	25	1.52	1.40	0.13	781
Mesothelioma	C45	8	0.49	0.51	0.07	1525
Kaposi Sarcoma	C46	40	2.44	2.17	0.22	446
Connective tissue	C49	21	1.28	1.29	0.13	771
Breast	C50	15	0.91	0.93	0.13	800
Penis	C60	9	0.55	0.52	0.04	2340
Prostate	C61	476	28.98	30.96	4.00	25
Testis	C62	9	0.55	0.45	0.04	2618
Other specified	C63	18	1.10	1.15	0.12	840
Kidney	C64	13	0.79	0.88	0.06	1595
Bladder	C67	46	2.80	2.88	0.29	344
Eye	C69	9	0.55	0.55	0.05	2186
Brain, CNS	C71	33	2.01	2.05	0.18	561
Thyroid	C73	6	0.37	0.37	0.05	2201
Endocrine	C74	5	0.30	0.30	0.03	3892
Ill defined	C76	13	0.79	0.80	0.10	988
Primary site unknown	C80	115	7.00	7.12	0.89	112
Hodgkin lymphoma	C81	34	2.07	2.13	0.17	595
Burkitt lymphoma	C83	2	0.12	0.13	0.01	11765
Non Hodgkin lymphoma	C84	66	4.02	4.03	0.40	248
Myeloma	C90	23	1.40	1.40	0.17	574
Leukaemia	C92	27	1.64	1.66	0.13	779
Haematology other	C96	5	0.30	0.29	0.03	3664

N includes cases with unknown age*

Table 2: Summary statistics for all cancers in Women, Ekurhuleni (2018)

Site	ICD10	N*	Crude Rate	ASR	Cum Risk 0-74	Lifetime Risk 0-74
All sites	All	2448	140.95	156.19	15.08	7
All sites but C44	All but C44	2017	116.14	123.88	12.52	8
Lip	C00	2	0.12	0.22	0.01	9804
Tongue	C02	5	0.29	0.30	0.04	2611
Mouth	C06	10	0.58	0.75	0.07	1416
Salivary gland	C07	6	0.35	0.35	0.03	3356
Naso-Oropharynx	C11	11	0.63	0.75	0.07	1382
Oesophagus	C15	31	1.78	2.32	0.23	439
Stomach	C16	20	1.15	1.22	0.11	879
Small intestine	C17	3	0.17	0.21	0.03	2968
Colorectal	C18	106	6.10	7.37	0.77	130
Anus	C21	21	1.21	1.01	0.10	1013
Liver & Bile duct	C22	33	1.90	2.10	0.25	395
Pancreas	C25	33	1.90	2.38	0.28	353
Larynx	C32	6	0.35	0.42	0.03	3130
Lung	C34	67	3.86	4.61	0.59	171
Bone	C41	9	0.52	0.45	0.03	3073
Melanoma	C43	42	2.42	3.02	0.24	419
Skin other	C44	16	0.92	1.08	0.09	1086
BCC	C44	290	16.70	21.14	2.11	47
SCC of skin	C44	125	7.20	10.10	0.75	134
Mesothelioma	C45	5	0.29	0.34	0.05	1995
Kaposi Sarcoma	C46	37	2.13	1.82	0.12	824
Connective tissue	C49	10	0.58	0.62	0.07	1335
Breast	C50	553	31.84	33.56	3.55	28
Vulva	C51	25	1.44	1.18	0.10	1042
Vagina	C52	4	0.23	0.24	0.03	3578
Cervix	C53	444	25.56	24.26	2.65	38
Uterus	C54	90	5.18	6.46	0.81	123
Ovary	C56	46	2.65	3.06	0.35	285
Other specified	C63	21	1.21	1.31	0.15	673
Kidney	C64	11	0.63	0.77	0.09	1167
Bladder	C67	24	1.38	1.56	0.20	495
Eye	C69	14	0.81	0.69	0.06	1775
Brain, CNS	C71	22	1.27	1.54	0.15	647
Thyroid	C73	29	1.67	1.56	0.18	551
Endocrine	C74	8	0.46	0.52	0.06	1681
Ill defined	C76	12	0.69	0.76	0.08	1230
Primary site unknown	C80	120	6.91	7.57	0.92	108
Hodgkin lymphoma	C81	22	1.27	1.20	0.12	867
Non Hodgkin lymphoma	C84	67	3.86	4.07	0.35	287
Myeloma	C90	18	1.04	1.33	0.14	723
Leukaemia	C92	22	1.27	1.51	0.09	1093
Haematology other	C96	8	0.46	0.46	0.05	2080

N includes cases with unknown age*

Figures 6-9 below illustrates the frequency and age-standardised incidence rates of the most common cancers registered in the EPBCR in 2018 for males and females. Frequency of cancers is useful for determining the burden on a country's health care systems of screening, diagnosis and treatment of cancers. Age-standardised incidence rates are used to compare rates of cancers between geographic regions and populations. Prostate cancer was by far the commonest cancer amongst men with 476 cases and an ASR of 30.96/100 000. Amongst women 551 new cases of breast cancer were reported with an ASR of 33.56/100 000. This was closely followed by cervical cancer with an ASR of 24.26/100 000.




Figure 6: Frequency of most common cancers in males

*Only cases with known ages included




Figure 7: Age Standardised Incidence Rates for common cancers in males




Figure 8: Frequency of top 10 common cancers in females

*Only cases with known ages included




Figure 9: Age standardised incidence rates for the common cancers in females




Figure 10: ASR of common cancers in men by population group




Figure 11: ASR of common cancers in women by population group

Results of Selected Cancers

Breast Cancer

Worldwide, there were approximately 2.1 million new cases of breast cancer diagnosed, accounting for a quarter of all cancers in women. Breast cancer is one of the commonest female cancers in the vast majority of countries and the leading cause of cancer death in over 100 countries globally. High incidence rates in developed and transitioning countries are driven by non-hereditary risk factors related to menstruation, reproduction, exogenous hormone replacement, alcohol intake and weight gain (12).

Breast cancer was the most commonly diagnosed cancer in women in the Ekurhuleni District with an ASR of 33.56/100 000 and a lifetime risk of 1:28 women. White and Asian women had the highest risk of breast cancer with ASR of 55 and 36 /100 000 respectively.

While the rates amongst Black women are lower than in White women at 25/100 000, this rate is higher than the national rates of breast cancer reported by the national pathology-based cancer registry of 18/100 000. This supports the motivation to develop population-based cancer registration for South Africa where the case definition is inclusive and where active surveillance is possible.

Cervical Cancer

Cervical cancer ranks as the fourth most common cancer worldwide and the fourth leading cause of cancer death in women. The highest regional incidence and mortality rates are seen in Africa, particularly Southern, Eastern and Western Africa. In many sub-Saharan African countries, cervical cancer is the most common cancer and the leading cause of cancer death in women (12).

Human Papillomavirus is a necessary, but not sufficient cause of cervical cancer. Other co factors in the aetiology of cervical cancer include immunosuppression (particularly infection with HIV), parity, smoking and oral contraceptive use. The WHO has recommended, and South Africa has implemented, vaccination against HPV in girls aged 9 to 13 years. Vaccination together with cervical cancer screening programs (more especially HPV based testing), has the potential to reduce the burden of cervical cancer in developing countries (12).

In Ekurhuleni, cervical cancer accounted for 18% of all cancers diagnosed in women in 2018 (n=444). The age-standardised incidence rate was 24.26/100 000 and 1:38 were at risk for

cervical cancer. Rates of cervical cancer were highest amongst black women at 31.1/100 000; the next highest being Coloured women with a rate of 14.8/100 000.

Colorectal Cancer

Colorectal cancer ranks third worldwide in terms of cancer incidence and second in terms of mortality. Interestingly, the disease is considered a marker of socioeconomic development, with rates being three-fold higher in high human development index (HDI) countries compared to lower HDI countries. However, case fatality rates remain high in low HDI countries. As economies transition, rates of colorectal cancer rise uniformly adding to the burden of disease in these countries. The rise in incidence in transitioning economies is influenced by changes in dietary patterns, obesity and other lifestyle factors (12).

In Ekurhuleni, there were 228 colorectal cancer cases diagnosed in males and females in 2018. Colorectal cancer was the second most common cancer diagnosed in men after prostate cancer and the third in women after breast and cervical cancer. Rates were highest in White and Coloured populations.

Prostate Cancer

Prostate cancer is the leading cause of cancer in men in over one half of the countries in the world and a leading cause of cancer death in many countries, particularly in sub – Saharan Africa (12). In South Africa, there were 476 cases of prostate cancer reported to the Ekurhuleni Population-Based Cancer Registry in 2018 resulting in an ASR for all males of 30.96/100 000 and a lifetime risk of 1:25 men. White males had the highest risk for prostate cancer and an ASR of 52.97/100 000. Black, Asian and Coloured men had ASR's ranging from 17-27/100 000. In the United States and the Caribbean, men of African Descent had the highest rates of prostate cancer influenced by genetic and ethnic predisposition. However, the same is not reflected in the South African data where Caucasian men had the highest rates. This may reflect the differential access to diagnosis and screening in the Black population who access health care in the public sector compared to the White population who frequent the private health sector.

Childhood cancers incidence

Table 3 below shows the top 10 cancers in children aged 0-14 years in the Ekurhuleni area. A total of 68 cancers were registered in 2018 among children. Paediatric cancers accounted for 1.45 % of all cancers registered in 2018. There were more cancers amongst young boys than girls. Leukaemias and lymphomas were the most common cancers amongst children.

Table 3: Childhood cancers

Cancer	Number of Cases						Rates per Million Age-Specific Rates						
	Age 0-4	Age 4-9	Age 10- 14	All ages	M/F Ratio	Relative Frequency	Age 0-4	Age 4-9	Age 10-14	Crude	ASR	LCL	UCL
Leukaemia	6	4	6	16	0.6	23.5	20.9	15.8	26.4	20.9	20.9	11.9	33.9
Lymphoma	3	6	7	16	1.7	23.5	10.5	23.7	30.8	20.9	20.6	11.8	33.5
CNS Neoplasms	1	4	1	6	1	8.8	3.5	15.8	4.4	7.8	7.7	2.8	16.9
Neuroblastoma	1	1	0	2	1	2.9	3.5	4.0	0.0	2.6	2.6	0.3	9.5
Retinoblastoma	3	0	0	3	2	4.4	10.5	0.0	0.0	3.9	4.1	0.8	11.7
Nephroblastoma – Wilms Tumour	4	1	0	5	4	7.3	14.0	4.0	0.0	6.5	6.7	2.2	15.5
Bone Tumours	0	0	1	1		1.5	0.0	0.0	4.4	1.3	1.3	0.0	7.2
Soft Tissue Sarcomas	5	1	1	7	0.8	10.3	17.5	4.0	4.4	9.1	9.3	3.7	19.1
Germ Cell Tumours	2	0	1	3	2	4.4	7.0	0.0	4.4	3.9	4.0	0.8	11.6
Primary site unknown	2	0	2	4	3	5.9	7.0	0.0	8.8	5.2	5.3	1.4	13.4
Other, specified	2	0	3	5	0.7	7.3	7.0	0.0	13.2	6.5	6.5	2.1	15.2
Total	29	17	22	68	1.2	100	101.2	67.2	96.8	88.7	89.0	38.0	187.6

Quality

a) Basis of Diagnosis

Table 4 demonstrates the proportion of cases morphologically verified (MV) using histology, cytology or bone marrow aspirate and trephine, diagnosed by clinical means or registered from death certificate-only information (DCO).

Table 4: Percentage of cases Morphologically Verified, diagnosed clinically or diagnosed by Death Certificate Only

ICD 10 Cancer Site	No. of Cases	(%Total)	Basis of diagnosis (%)		
			DCO	Clinical	MV
C00 Lip	8	0.17	0.0	0.0	100.0
C02 Tongue	19	0.40	0.0	5.3	94.7
C06 Mouth	24	0.51	0.0	4.2	95.8
C07 Salivary gland	13	0.28	0.0	7.7	92.3
C11 Naso-Oropharynx	38	0.81	0.0	10.5	89.5
C15 Oesophagus	96	2.04	1.0	6.3	92.7
C16 Stomach	47	1.00	0.0	2.1	97.9
C17 Small intestine	9	0.19	0.0	0.0	100.0
C18-20 Colorectal	228	4.85	0.0	2.2	97.8
C21 Anus	36	0.77	0.0	11.1	88.9
C22 Liver & Bile duct	65	1.38	4.6	13.8	81.5
C25 Pancreas	61	1.30	0.0	8.2	91.8
C26,C38,C48,C57,C58,C63,C68 Other specified	39	0.83	0.0	2.6	97.4
C32 Larynx	22	0.47	0.0	4.5	95.5
C34 Lung	149	3.17	1.3	6.0	92.6
C41 Bone	24	0.51	0.0	8.3	91.7
C43 Melanoma	115	2.45	0.0	0.9	97.4
C44 BCC	779	16.58	0.0	0.1	98.5
C44 SCC of skin	316	6.73	0.0	0.6	98.1
C44 Skin other	41	0.87	0.0	4.9	95.1
C45 Mesothelioma	13	0.28	0.0	0.0	100.0
C46 Kaposi Sarcoma	77	1.64	0.0	5.2	93.5
C49 Connective tissue	31	0.66	0.0	0.0	100.0
C50 Breast	568	12.09	0.7	1.4	97.5
C51 Vulva	25	0.53	0.0	0.0	100.0
C52 Vagina	4	0.09	0.0	0.0	100.0
C53 Cervix	444	9.49	0.0	7.0	92.6
C54 Uterus	90	1.92	0.0	4.4	94.4
C56 Ovary	46	1.00	4.3	8.5	87.2
C60 Penis	9	0.19	0.0	0.0	100.0
C61 Prostate	476	10.13	0.0	1.5	97.7
C62 Testis	9	0.19	0.0	11.1	88.9
C64 Kidney	24	0.51	0.0	0.0	95.8
C67 Bladder	70	1.49	1.4	0.0	97.1
C69 Eye	23	0.49	0.0	4.3	95.7
C71 Brain, CNS	55	1.17	0.0	7.3	92.7
C73 Thyroid	35	0.74	0.0	2.9	97.1
C74 Endocrine	13	0.28	0.0	7.7	92.3
C76 Ill defined	25	0.53	0.0	8.0	92.0
C80 Primary site unknown	235	5.00	0.0	4.7	95.3

C81 Hodgkin lymphoma	56	1.19	0.0	5.4	94.6
C83 Burkitt lymphoma	2	0.04	0.0	0.0	100.0
C85 Non Hodgkin lymphoma	133	2.83	0.0	0.8	98.5
C90 Myeloma	41	0.87	0.0	9.8	90.2
C92 Leukaemia	49	1.04	0.0	14.3	83.7
C96 Haematology other	13	0.28	0.0	15.4	84.6
All Sites Total	4695	100	0.3	3.2	95.8

b) Primary site unknown (PSU)

There were 235 cases of cancer (5%) reported where the primary site was unspecified or uncertain from the available documentation. The rates of PSU were 7.12 and 7.57 /100 000 in men and women respectively.

c) Age unknown

There were seven cases of cancer with unknown age amongst females and two amongst males.

DISCUSSION

This is the second year of complete data collection from the Ekurhuleni Population-Based Cancer Registry, which covers approximately 6% of the South African population. The Ekurhuleni Registry is based in an urban municipality with an appropriate representation of the different population groups in South Africa. The case definition for the EPBCR includes all confirmed cases of cancer (confirmed by pathology/laboratory test, clinically or radiologically) diagnosed in a resident of the Ekurhuleni Municipality.

We found the most common cancers registered in the EPBCR to be prostate, colorectal and lung amongst men and breast, cervix and colorectal amongst women. Leukaemia was the most common cancer diagnosed in children. Over 95% of all cancers were morphologically verified. 5% of cancers had an uncertain primary site and of these 95% had a pathology report. There were nine cancer cases notified with an unknown age.

The patterns of cancer in men and women are similar to the previous year's data as well as the national pathology-based cancer registry rankings, with a few exceptions. In 2017, the leading cancers in Ekurhuleni were prostate, colorectal, lung, breast and cervix. In 2018, in addition to these common cancers, it is interesting to note the presence of melanoma skin cancer in the top 10 cancers amongst men and women. This is evidently driven by the high rate of melanoma skin cancer amongst the White population in Ekurhuleni.

Morphological verification in the EPBCR is high at over 95%. This may be a representation of abundant access to laboratory services in both the public and private healthcare sectors of South Africa resulting in significant numbers of biopsy confirmed cancers. However it could also point to over-reliance on reporting from pathology-based diagnosis from the perspective of the EPBCR resulting in clinically diagnosed cases being missed.

In the previous year, there were 110 cases of cancer reported where the age of the patient was unknown. This has improved considerably in 2018 with only nine cases of unknown age. This has been the result of a concerted effort by surveillance officers and management to obtain missing information and to quality assure this variable prior to analysis.

Unknown primary site poses significant challenges to cancer registration. In many instances, the site of the primary is truly obscure to the clinician as well as the cancer registrar. However, there may be instances where insufficient information is available to the cancer registrar to record the primary site. In the 2018 EPBCR data, 95% of PSU's had a pathology report

implying that the primary site was unclear to the pathologist as well. In the future, work is required to determine the percentage of PSU that can be re-allocated to a specific site if more information is available.

Much work has been conducted on the 2018 data to ensure high quality of the information reported. Each notification was checked for inconsistencies by the EPBCR manager. Initial cleaning of the database was conducted by a medical scientist and missing and inconsistent variables were referred back to the surveillance officers for correction. Similarly, during analysis, systematic inconsistencies were corrected. This has resulted in a template for quality assurance for the future and a high quality dataset for the 2018 year.

For this year, we have also intensified case finding. An epidemiologist from the NCR was successful in her application for a UICC grant that allowed her to visit the Zimbabwean Cancer Registry to determine additional methods for case finding. The new case finding strategies learnt during this Fellowship were implemented in the EPBCR on her return to South Africa. This resulted in 1318 more cases being reported in the 2018 year (n=4695) compared to 2017 (n=3371).

In the coming year, the EPBCR will focus on an external evaluation of the registry. A protocol for this evaluation is currently under development, and will focus on the completeness, timeliness, comparability and validity of the EPBCR. Enhancement of case finding will continue as well as the ongoing QA/QC plan implemented in the financial year.

The combined information provided by the Ekurhuleni PBCR and the national pathology-based cancer registry provide an important snapshot of the cancer landscape in South Africa. It is reassuring that the leading cancers in both registries are similar providing reliable information for policy making and healthcare interventions. For two of the top five cancers (breast and cervical cancer) national prevention and control policies are already in place. However, policies are still required for the remaining top cancers in the country and implementation of existing policy guidelines requires enhancement.

With this pilot site in Ekurhuleni, the NCR has demonstrated that a population-based cancer registry is feasible and indeed, can be successful in the local context. Aided by local and regional partners, the EPBCR aims to become the preeminent source of cancer statistics for the country and an example of excellence for population-based cancer registries on the continent. We look forward to working with our stakeholders to realise this vision.

REFERENCES

1. Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. *Eur J Cancer* [Internet]. 2009 Mar [cited 2014 Aug 20];45(5):756–64. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19128954>
2. Singh E, Underwood JM, Nattey C, Babb C, Sengayi M, Kellett P. South African National Cancer Registry: Effect of withheld data from private health systems on cancer incidence estimates. *South African Med J* [Internet]. 2015;105(2):107. Available from: <http://www.samj.org.za/index.php/samj/article/view/8858>
3. Department of Health. Regulations relating to cancer registration. *National Health Act, 2003. Gov Gaz.* 2011;(34248):2–8.
4. Singh E, Ruff P, Babb C, Sengayi M, Beery M, Khoali L, et al. Establishment of a cancer surveillance programme: The South African experience. *Lancet Oncol.* 2015;16(8).
5. Singh E, Ruff P, Babb C, Sengayi M, Beery M, Khoali L, et al. Establishment of a cancer surveillance programme: The South African experience. Vol. 16, *The Lancet Oncology*. NIH Public Access; 2015. p. e414–21.
6. Ekurhuleni Metropolitan Municipality. ANNEXURE A Integrated Development Plan DRAFT. 2016.
7. INTEGRATED, (IDP) DP, OF, OF C, EKURHULENI. full-text. 2018.
8. Statistics South Africa. Provincial Profile: Gauteng Community Survey 2016. *Prov Profile Gauteng Community Surv 2016.* 2018;(03-01–09):1–91.
9. KwaZulu-Natal Department of Health. Referral system: levels of care. 2014. p. 2017.
10. NHLS. 2017/18 NHLS Annual Report. Sandringham; 2018.
11. Parliament of the Republic of south Africa. Protection of Personal Information Act, 2013 Ensuring protection of your personal information and effective access to information. 2013;(4):154.
12. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* [Internet]. 2018 Nov;68(6):394–424. Available from: <http://doi.wiley.com/10.3322/caac.21492>

APPENDICES

Appendix 1: List of Data Sources

PUBLIC HOSPITALS

- ❖ Charlotte Maxeke Johannesburg Academic Hospital
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Tshwane District Hospital
- ❖ Phelosong Regional Hospital
- ❖ Far East Rand Regional Hospital
- ❖ Thelle Mogoerane Regional Hospital
- ❖ Tembisa Regional Hospital
- ❖ Tambo Memorial Regional Hospital
- ❖ Edenvale Hospital

PRIVATE HEALTH FACILITIES

- ❖ Benoni Oncology Centre
- ❖ Gauteng Prostate Oncology - Morehill Clinic
- ❖ Gauteng Oncology - Benoni Oncology Centre
- ❖ Gauteng Oncology - Linmed Hospital
- ❖ Netcare Clinton Oncology
- ❖ Independent Practitioners

HOSPICES

- ❖ East Rand Hospice
- ❖ Flora Madiba Hospice
- ❖ Stepping Stone Hospice
- ❖ St Francis Hospice

SOUTH AFRICAN ONCOLOGY CONSORTIUM

- ❖ Private Oncologists


PAEDIATRIC ONCOLOGY

- ❖ CHOC Childhood cancer foundation
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Donald Gordon Medical Oncology Unit

NHLS

- ❖ CDW pathology based cancer reports

Appendix 2: South African Cancer Notification Form

	health Department: Health REPUBLIC OF SOUTH AFRICA National Health Act, 2003 (Act No. 61 of 2003) Regulation Number 380	Republic of South Africa Department of Health CANCER REGISTRATION FORM	To be completed in duplicate in BLOCK LETTERS . Please mark with <input checked="" type="checkbox"/> the CORRECT box, where required. Original to be submitted to the National Cancer Register and copy to be retained: To be submitted to the National Cancer Register via: e-mail: cancer.registry@nhls.ac.za fax: 011 489 9132 / 011 489 9152 Post: P.O. Box 1038, Johannesburg, 2000
A. PARTICULARS OF INDIVIDUAL			
1. Name of facility 			
USE PATIENT STICKER <i>if available</i>			
2. Surname 			
3. Full names 			
4. Date of birth 			
5. Folder number 			
6. Sex <input type="checkbox"/> Male <input type="checkbox"/> Female			
7. ID number/Passport number 			
8. Race group <input type="checkbox"/> African <input type="checkbox"/> Coloured <input type="checkbox"/> White <input type="checkbox"/> Indian <input type="checkbox"/> Other _____			
9. Area of residence			
9.1 City/town/village 			
9.2 Postal code 			
9.3 How long at this address? years			
Please record place of birth if not the same as current address			
9.4 City/town/village 			
9.5 Postal code 			
B. RISK FACTOR PROFILE			
10. Usual occupation of patient (If retired, give type of work done for most of working life)			
11. Type of industry/business (eg Mining, farming etc)			
12. Did the patient ever smoke tobacco? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown			
13. Did the patient ever consume alcohol regularly? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown (that is, more than once a week)			
14. HIV status <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Unknown			
C. CLINICAL AND LABORATORY DETAILS			
15. Date of diagnosis 			
16. Cancer diagnosis and Histology 17. ICD-10 • <i>Please give all information available on the site, laterality, histology and behaviour of the tumour</i> _____ _____			
18. Grade <input type="checkbox"/> Well differentiated <input type="checkbox"/> Moderately differentiated <input type="checkbox"/> Poorly differentiated <input type="checkbox"/> Unknown/Not applicable			
19. Stage <input type="checkbox"/> Primary/localised <input type="checkbox"/> Metastatic <input type="checkbox"/> Unknown/Not applicable			
20. Invasiveness <input type="checkbox"/> In-situ <input type="checkbox"/> Invasive			
21. Basis of diagnosis <input type="checkbox"/> Clinical <input type="checkbox"/> Clinical with investigation <input type="checkbox"/> Cytology/histopathology <input type="checkbox"/> Molecular <input type="checkbox"/> Death Certificate			
22. Prescribed treatment <input type="checkbox"/> Surgery <input type="checkbox"/> Radiation <input type="checkbox"/> Chemotherapy <input type="checkbox"/> Other <input type="checkbox"/> Palliation <input type="checkbox"/> Alternative <input type="checkbox"/> None			
INFORMANT PARTICULARS		OFFICE CODING	
Name (Print) _____		 • 	
MP/NC Number 		M - / / 	
Signature _____ Date _____			

Appendix 3: Tables of Incidence by site, sex, age group and population group Ekurhuleni 2018

Tables of ASR and Crude Incidence by population group

Asian Females: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Breast	12	46.15	12	37.07	36.36	18.45	65.13
Pancreas	0	0.00	1	3.09	8.31	0.21	35.29
Primary site unknown	3	11.54	3	9.27	8.19	1.52	26.75
Colorectal	2	7.69	2	6.18	6.83	0.71	25.94
Non Hodgkin lymphoma	2	7.69	2	6.18	6.46	0.73	24.78
Cervix	2	7.69	2	6.18	4.87	0.59	21.03
Uterus	1	3.85	1	3.09	4.47	0.11	22.93
Hodgkin lymphoma	1	3.85	1	3.09	2.98	0.08	18.83
Oesophagus	1	3.85	1	3.09	2.55	0.06	17.79
Thyroid	1	3.85	1	3.09	1.97	0.05	16.53
Bladder	1	3.85	1	3.09	1.97	0.05	16.53

Black Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Cervix	385	30.80	389	29.21	31.09	27.93	34.5
Breast	291	23.28	299	22.45	25.16	22.25	28.33
Uterus	66	5.28	68	5.11	7.41	5.73	9.4
Primary site unknown	77	6.16	80	6.01	7.33	5.76	9.2
Colorectal	37	2.96	40	3	3.57	2.52	4.91
Non Hodgkin lymphoma	39	3.12	39	2.93	2.89	2.02	4.02
Oesophagus	24	1.92	24	1.8	2.68	1.7	3.99
BCC	13	1.04	30	2.25	2.66	1.76	3.85
Ovary	26	2.08	26	1.95	2.42	1.55	3.59
Kaposi Sarcoma	34	2.72	34	2.55	1.99	1.36	2.85
Liver & Bile duct	17	1.36	17	1.28	1.41	0.8	2.3
Vulva	21	1.68	21	1.58	1.35	0.81	2.15
Stomach	13	1.04	14	1.05	1.25	0.66	2.15
Thyroid	14	1.12	15	1.13	1.24	0.67	2.11
Hodgkin lymphoma	16	1.28	16	1.2	1.15	0.65	1.93
Anus	16	1.28	17	1.28	1.14	0.64	1.91
SCC of skin	12	0.96	13	0.98	1.1	0.55	1.96
Lung	10	0.80	11	0.83	1.09	0.54	1.95
Leukaemia	13	1.04	13	0.98	1	0.52	1.77
Myeloma	10	0.80	10	0.75	0.96	0.45	1.78
Eye	14	1.12	14	1.05	0.93	0.49	1.63
Bladder	9	0.72	10	0.75	0.92	0.43	1.72
Ill defined	9	0.72	9	0.68	0.8	0.35	1.54
Pancreas	8	0.64	9	0.68	0.79	0.35	1.53
Skin other	9	0.72	9	0.68	0.77	0.35	1.5
Other specified	8	0.64	9	0.68	0.69	0.31	1.34
Connective tissue	8	0.64	8	0.6	0.64	0.27	1.31
Naso-Oropharynx	7	0.56	7	0.53	0.61	0.24	1.28
Melanoma	4	0.32	5	0.38	0.6	0.19	1.37
Bone	7	0.56	7	0.53	0.49	0.19	1.07
Haematology other	5	0.40	6	0.45	0.47	0.17	1.07
Mouth	4	0.32	5	0.38	0.46	0.14	1.1
Brain, CNS	4	0.32	5	0.38	0.45	0.15	1.07
Larynx	4	0.32	4	0.3	0.44	0.12	1.09
Salivary gland	5	0.40	5	0.38	0.39	0.12	0.96
Kidney	3	0.24	3	0.23	0.33	0.07	0.94
Vagina	3	0.24	3	0.23	0.28	0.05	0.84
Endocrine	3	0.24	3	0.23	0.28	0.06	0.82
Lip	1	0.08	1	0.08	0.16	0	0.71
Tongue	0	0.00	1	0.08	0.08	0	0.5
Small Intestine	1	0.08	1	0.08	0.08	0	0.49

Coloured Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	11	31.43	11	24.66	22.56	11.16	41.22
Cervix	7	20.00	7	15.69	14.75	5.6	31.72
Primary site unknown	3	8.57	3	6.73	8.27	1.7	23.56
Colorectal	3	8.57	3	6.73	6.61	1.33	20.01
Melanoma	2	5.71	2	4.48	3.59	0.35	15.07
Leukaemia	1	2.86	1	2.24	2.95	0.07	15.17
Non Hodgkin lymphoma	1	2.86	1	2.24	2.95	0.07	15.17
Lung	1	2.86	1	2.24	2.66	0.07	14.34
BCC	0	0.00	1	2.24	2.66	0.07	14.33
Uterus	1	2.86	1	2.24	2.66	0.07	14.33
Pancreas	1	2.86	1	2.24	2.66	0.07	14.33
Liver & Bile duct	1	2.86	1	2.24	1.9	0.05	12.31
Other specified	1	2.86	1	2.24	1.9	0.05	12.31
Ovary	1	2.86	1	2.24	1.86	0.05	12.2
Thyroid	0	0.00	1	2.24	1.84	0.05	12.14
SCC of skin	1	2.86	1	2.24	1.67	0.04	11.74

White Females: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	224	22.16	231	98.87	55.82	48.37	64.28
BCC	237	23.44	259	110.86	55.04	48.02	63.04
SCC of skin	91	9.00	111	47.51	18.8	14.92	23.68
Colorectal	59	5.84	61	26.11	11.89	8.92	15.87
Cervix	44	4.35	46	19.69	11.86	8.55	16.28
Lung	52	5.14	55	23.54	11.24	8.27	15.25
Melanoma	31	3.07	35	14.98	8.75	5.84	12.83
Primary site unknown	31	3.07	34	14.55	8.34	5.59	12.24
Non Hodgkin lymphoma	25	2.47	25	10.7	6.91	4.04	11.12
Pancreas	20	1.98	22	9.42	4.54	2.76	7.45
Uterus	19	1.88	20	8.56	4.09	2.41	6.92
Thyroid	12	1.19	12	5.14	3.91	1.9	7.3
Ovary	17	1.68	19	8.13	3.85	2.17	6.73
Brain, CNS	17	1.68	17	7.28	3.59	2.01	6.35
Other specified	10	0.99	11	4.71	2.87	1.38	5.64
Liver & Bile duct	14	1.38	15	6.42	2.65	1.44	5.03
Leukaemia	8	0.79	8	3.42	2.41	0.66	5.92
Kidney	7	0.69	8	3.42	2.41	0.77	5.64
Bladder	13	1.29	13	5.56	2.29	1.18	4.6
Hodgkin lymphoma	5	0.49	5	2.14	1.59	0.43	4.25
Endocrine	5	0.49	5	2.14	1.51	0.44	4.02
Skin other	7	0.69	7	3	1.5	0.55	3.79
Myeloma	7	0.69	8	3.42	1.41	0.58	3.53
Oesophagus	6	0.59	6	2.57	1.38	0.5	3.61
Stomach	6	0.59	6	2.57	1.33	0.44	3.6
Connective tissue	2	0.20	2	0.86	1.25	0.07	4.73
Anus	4	0.40	4	1.71	1.24	0.31	3.63
Vulva	4	0.40	4	1.71	1.06	0.25	3.34
Tongue	4	0.40	4	1.71	0.96	0.25	3.09
Ill defined	3	0.30	3	1.28	0.88	0.16	3.12
Mouth	5	0.49	5	2.14	0.84	0.26	2.81
Mesothelioma	5	0.49	5	2.14	0.8	0.26	2.74
Bone	2	0.20	2	0.86	0.74	0.09	3.01
Naso-Oropharynx	4	0.40	4	1.71	0.73	0.18	2.72
Kaposi Sarcoma	2	0.20	3	1.28	0.61	0.11	2.61
Small intestine	2	0.20	2	0.86	0.45	0.05	2.42
Larynx	2	0.20	2	0.86	0.43	0.04	2.43
Haematology other	2	0.20	2	0.86	0.41	0.05	2.34
Vagina	1	0.10	1	0.43	0.32	0.01	2.33
Lip	1	0.10	1	0.43	0.28	0.01	2.23
Salivary gland	1	0.10	1	0.43	0.11	0	1.95

Asian Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	5	20.83	5	14.28	18.93	6.14	46.61
Primary site unknown	3	12.50	4	11.42	13.22	3.56	37.85
Colorectal	3	12.50	3	8.57	7.81	1.46	29.65
BCC	0	0.00	2	5.71	5.05	0.43	26.29
Non Hodgkin lymphoma	1	4.17	1	2.86	4.41	0.11	26.72
SCC of skin	0	0.00	1	2.86	3.98	0.1	25.67
Naso-Oropharynx	1	4.17	1	2.86	3.72	0.09	25.05
Lung	1	4.17	1	2.86	3.72	0.09	25.05
Melanoma	1	4.17	1	2.86	3.29	0.08	24.08
Oesophagus	1	4.17	1	2.86	3.29	0.08	24.08
Testis	1	4.17	1	2.86	2.87	0.07	23.18
Liver & Bile duct	1	4.17	1	2.86	2.76	0.07	22.97
Pancreas	1	4.17	1	2.86	2.76	0.07	22.97
Kidney	1	4.17	1	2.86	2.69	0.07	22.82
Mouth	1	4.17	1	2.86	2.27	0.06	22.06
Lip	1	4.17	1	2.86	1.94	0.05	21.5
Hodgkin lymphoma	1	4.17	1	2.86	1.33	0.03	20.62
Endocrine	1	4.17	1	2.86	1.33	0.03	20.62

Black Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	222	28.91	231	16.15	27.23	23.68	31.13
Primary site unknown	66	8.59	69	4.82	6.03	4.58	7.78
Oesophagus	36	4.69	36	2.52	4	2.73	5.63
Colorectal	38	4.95	40	2.8	4	2.76	5.58
BCC	11	1.43	40	2.8	3.84	2.69	5.31
Non Hodgkin lymphoma	40	5.21	42	2.94	3.14	2.21	4.36
Kaposi Sarcoma	36	4.69	36	2.52	2.58	1.74	3.72
Lung	23	2.99	25	1.75	2.3	1.43	3.5
SCC of skin	17	2.21	26	1.82	2.17	1.36	3.3
Hodgkin lymphoma	26	3.39	27	1.89	2.07	1.33	3.09
Leukaemia	20	2.60	20	1.4	1.58	0.93	2.54
Naso-Oropharynx	17	2.21	17	1.19	1.54	0.87	2.53
Larynx	14	1.82	15	1.05	1.51	0.83	2.53
Stomach	15	1.95	15	1.05	1.28	0.69	2.19
Liver & Bile duct	15	1.95	16	1.12	1.22	0.66	2.08
Melanoma	7	0.91	9	0.63	1.14	0.47	2.23
Connective tissue	13	1.69	14	0.98	1.06	0.57	1.86
Ill defined	11	1.43	11	0.77	0.92	0.44	1.73
Anus	13	1.69	13	0.91	0.91	0.46	1.65
Skin other	11	1.43	12	0.84	0.86	0.4	1.63
Pancreas	8	1.04	8	0.56	0.85	0.35	1.7
Mouth	8	1.04	8	0.56	0.83	0.35	1.66
Other specified	7	0.91	8	0.56	0.81	0.33	1.64
Bone	10	1.30	10	0.7	0.74	0.33	1.46
Bladder	7	0.91	7	0.49	0.68	0.24	1.46
Myeloma	9	1.17	9	0.63	0.67	0.29	1.36
Eye	9	1.17	9	0.63	0.67	0.29	1.35
Brain, CNS	8	1.04	8	0.56	0.64	0.26	1.34
Tongue	6	0.78	6	0.42	0.59	0.2	1.33
Breast	6	0.78	6	0.42	0.55	0.19	1.26
Penis	8	1.04	8	0.56	0.53	0.22	1.14
Kidney	5	0.65	5	0.35	0.49	0.16	1.16
Thyroid	4	0.52	4	0.28	0.43	0.12	1.1
Small intestine	5	0.65	5	0.35	0.34	0.11	0.9
Mesothelioma	2	0.26	2	0.14	0.3	0.03	0.99
Salivary gland	4	0.52	4	0.28	0.3	0.07	0.85
Testis	3	0.39	3	0.21	0.25	0.05	0.8
Haematology other	2	0.26	3	0.21	0.18	0.04	0.65
Endocrine	2	0.26	2	0.14	0.16	0.02	0.66
Burkitt lymphoma	2	0.26	2	0.14	0.14	0.01	0.62

Coloured Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	4	13.79	4	9.71	17.92	4.34	46.62
Colorectal	6	20.69	6	14.56	17.35	5.63	41.84
BCC	3	10.34	3	7.28	11.24	2.19	34.23
Non Hodgkin lymphoma	2	6.90	2	4.85	8.5	0.64	32.66
Primary site unknown	3	10.34	3	7.28	7.17	1.45	25.72
Other specified	2	6.90	2	4.85	5.51	0.66	23.93
Tongue	1	3.45	1	2.43	4.71	0.12	25.05
Stomach	1	3.45	1	2.43	4.71	0.12	25.05
Oesophagus	1	3.45	1	2.43	4.71	0.12	25.05
Pancreas	1	3.45	2	4.85	3.84	0.46	20.7
Bladder	1	3.45	1	2.43	2.63	0.07	19.78
Kaposi Sarcoma	1	3.45	1	2.43	1.84	0.05	18.24
Melanoma	1	3.45	1	2.43	1.84	0.05	18.23
Haematology other	1	3.45	1	2.43	1.6	0.04	17.84
Hodgkin lymphoma	1	3.45	1	2.43	1.22	0.03	17.27

White Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
BCC	411	32.83	444	192.87	105.03	95.1	115.95
Prostate	207	16.53	236	102.52	52.97	46.19	60.72
SCC of skin	149	11.90	164	71.24	36.56	30.95	43.17
Colorectal	70	5.59	73	31.71	17.81	13.84	22.85
Melanoma	61	4.87	62	26.93	15.37	11.61	20.22
Lung	56	4.47	56	24.33	12.2	9.11	16.33
Bladder	34	2.72	38	16.51	8.55	5.95	12.25
Primary site unknown	33	2.64	39	16.94	8.15	5.73	11.63
Brain, CNS	25	2.00	25	10.86	7.02	4.34	10.94
Non Hodgkin lymphoma	20	1.60	21	9.12	6.41	3.65	10.54
Oesophagus	26	2.08	27	11.73	6.34	4.11	9.69
Pancreas	15	1.20	17	7.38	3.97	2.26	6.87
Liver & Bile duct	15	1.20	15	6.52	3.45	1.89	6.21
Skin other	10	0.80	13	5.65	3.13	1.62	5.86
Myeloma	14	1.12	14	6.08	2.97	1.59	5.54
Stomach	11	0.88	11	4.78	2.67	1.28	5.32
Hodgkin lymphoma	5	0.40	5	2.17	2.55	0.7	6.21
Leukaemia	7	0.56	7	3.04	2.54	0.83	5.84
Kidney	7	0.56	7	3.04	2.52	0.72	6.08
Naso-Oropharynx	8	0.64	9	3.91	2.33	0.95	5.07
Testis	5	0.40	5	2.17	2	0.64	4.83
Breast	7	0.56	9	3.91	1.94	0.86	4.3
Bone	5	0.40	5	2.17	1.91	0.5	4.96
Connective tissue	7	0.56	7	3.04	1.88	0.73	4.38
Tongue	7	0.56	7	3.04	1.83	0.72	4.28
Lip	5	0.40	5	2.17	1.67	0.48	4.36
Mouth	3	0.24	5	2.17	1.67	0.48	4.36
Other specified	8	0.64	8	3.48	1.62	0.67	3.85
Mesothelioma	6	0.48	6	2.61	1.32	0.45	3.55
Kaposi Sarcoma	0	0.00	3	1.3	0.78	0.14	2.91
Thyroid	2	0.16	2	0.87	0.63	0.08	2.76
Endocrine	2	0.16	2	0.87	0.55	0.07	2.6
Salivary gland	3	0.24	3	1.3	0.53	0.11	2.44
Anus	2	0.16	2	0.87	0.35	0.04	2.24
Ill defined	2	0.16	2	0.87	0.35	0.04	2.24
Larynx	1	0.08	1	0.43	0.3	0.01	2.28
Haematology other	1	0.08	1	0.43	0.3	0.01	2.28
Small intestine	1	0.08	1	0.43	0.18	0	2.04
Penis	1	0.08	1	0.43	0.14	0	1.99

Age Specific Incidence Rates /100 000 and Lifetime Risk reported as 1: x

ALL FEMALES																						
Site	All ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	2441	7	9.8	6.2	7.9	8.8	12.5	30.6	78.8	85.1	129.0	173.2	238.2	385.3	592.9	574.3	937.3	1418.3	1816.6	2242.1	7.00	
All sites but c44	2010	7	8.4	6.2	7.9	8.8	11.1	28.9	73.1	81.2	118.9	156.4	215.8	331.1	484.5	473.2	669.0	920.4	1097.6	1217.9	8.00	
Lip	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	27.7	9804.00	C00
Tongue	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	4.4	0.0	2.2	0.0	0.0	0.0	0.0	2611.00	C02
Mouth	10	0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.7	0.0	0.0	1.5	2.0	2.2	7.2	7.5	18.9	27.7	1416.00	C06
Salivary gland	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.0	1.1	1.5	0.0	2.2	0.0	0.0	18.9	0.0	3356.00	C07
Naso-oropharynx	11	0	0.0	0.0	0.9	0.0	0.0	0.0	0.6	0.0	0.0	1.7	0.0	1.5	4.1	2.2	3.6	7.5	18.9	0.0	1382.00	C11
Oesophagus	31	0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	1.1	10.3	10.2	8.6	14.3	30.2	18.9	83.0	439.00	C15
Stomach	20	0	0.0	0.0	0.0	0.0	0.7	0.6	0.6	0.6	1.3	0.8	1.1	2.9	4.1	6.4	3.6	22.6	18.9	0.0	879.00	C16
Small intestine	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	2.0	0.0	3.6	0.0	0.0	0.0	2968.00	C17
Colorectal	104	2	0.0	0.0	0.0	0.0	0.0	1.1	0.6	1.1	4.0	5.9	8.9	14.6	38.8	36.6	42.9	67.9	189.2	83.0	130.00	C18
Anus	21	0	0.0	0.0	0.0	0.0	0.0	1.1	1.3	2.8	2.0	2.5	2.2	0.0	2.0	2.2	3.6	7.5	0.0	0.0	1013.00	C21
Liver & Bile duct	33	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.3	4.2	3.3	4.4	4.1	10.8	21.5	30.2	0.0	27.7	395.00	C22
Pancreas	33	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.8	5.6	4.4	10.2	8.6	25.0	7.5	18.9	83.0	353.00	C25
Larynx	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.5	4.1	0.0	0.0	15.1	0.0	0.0	3130.00	C32
Lung	66	1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.6	0.7	0.0	7.8	16.1	14.3	23.7	53.7	67.9	56.8	27.7	171.00	C34
Bone	9	0	0.7	0.0	0.0	0.9	0.0	0.0	1.9	0.6	1.3	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3073.00	C41
Melanoma	42	0	0.0	0.0	0.0	0.0	0.0	1.1	1.3	1.1	2.0	0.8	4.5	2.9	8.2	15.1	10.7	30.2	56.8	138.4	419.00	C43
Skin other	16	0	0.7	0.0	0.0	0.0	0.7	0.6	0.0	0.0	0.0	1.7	0.0	4.4	6.1	4.3	0.0	15.1	18.9	0.0	1086.00	C44
Bcc	290	0	0.0	0.0	0.0	0.0	0.7	1.1	3.8	3.4	8.1	11.8	20.1	44.0	87.9	60.2	186.0	271.6	416.3	553.6	47.00	C44
Scc of skin	125	0	0.7	0.0	0.0	0.0	0.0	0.0	1.9	0.6	2.0	3.4	2.2	5.9	14.3	36.6	82.3	211.2	283.9	470.6	134.00	C44
Mesothelioma	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	3.6	7.5	0.0	0.0	1995.00	C45
Kaposi Sarcoma	37	0	0.0	0.0	0.9	0.0	1.3	6.1	5.7	1.7	3.4	0.8	2.2	0.0	0.0	2.2	0.0	0.0	0.0	55.4	824.00	C46
Connective tissue	10	0	1.4	0.0	0.0	0.0	0.7	0.0	0.0	0.6	0.0	0.8	0.0	4.4	0.0	0.0	7.2	0.0	0.0	0.0	1335.00	C49
Breast	551	2	0.0	0.0	0.0	0.0	2.0	3.9	16.5	22.5	37.0	56.3	67.1	93.8	126.8	118.3	178.9	286.7	264.9	332.2	28.00	C50

Vulva	25	0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	4.0	2.7	3.4	1.1	1.5	4.1	0.0	0.0	15.1	0.0	0.0	1042.00	C51
Vagina	4	0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.8	0.0	0.0	2.0	2.2	0.0	0.0	0.0	0.0	3578.00	C52
Cervix	443	1	0.0	0.0	0.0	0.0	0.0	5.0	25.4	25.4	43.0	53.0	53.7	74.7	89.9	73.1	93.0	98.1	94.6	55.4	38.00	C53
Uterus	90	0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.7	1.7	4.5	17.6	42.9	40.9	53.7	60.3	56.8	83.0	123.00	C54
Ovary	46	0	0.0	0.0	0.0	0.0	0.7	0.6	0.6	0.6	0.7	1.7	10.1	5.9	10.2	21.5	17.9	22.6	18.9	55.4	285.00	C56
Other specified	21	0	0.0	0.0	0.0	0.9	0.7	0.0	0.6	0.0	1.3	3.4	1.1	4.4	10.2	0.0	7.2	7.5	0.0	0.0	673.00	C63
Kidney	11	0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	4.1	4.3	3.6	15.1	0.0	0.0	1167.00	C64
Bladder	24	0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.6	0.0	0.0	2.2	5.9	4.1	8.6	17.9	22.6	18.9	0.0	495.00	C67
Eye	14	0	0.7	0.0	0.0	0.0	0.7	0.6	2.5	1.1	0.0	2.5	1.1	0.0	2.0	0.0	0.0	0.0	0.0	0.0	1775.00	C69
Brain, cns	21	1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	4.5	7.3	4.1	6.4	7.2	7.5	37.8	27.7	647.00	C71
Thyroid	29	0	0.0	0.0	0.9	0.0	0.7	1.1	1.9	2.3	2.0	2.5	2.2	1.5	4.1	6.4	10.7	7.5	0.0	0.0	551.00	C73
Endocrine	8	0	0.7	0.8	0.9	0.0	0.0	0.0	1.3	0.0	0.0	0.0	1.1	0.0	0.0	0.0	7.2	0.0	0.0	0.0	1681.00	C74
Ill defined	12	0	0.0	0.0	0.0	0.9	0.0	0.0	0.6	0.6	0.7	0.0	2.2	1.5	4.1	2.2	3.6	0.0	18.9	0.0	1230.00	C76
Primary site unknown	120	0	0.7	0.0	0.0	1.8	0.0	2.2	3.2	5.6	3.4	4.2	11.2	22.0	45.0	36.6	50.1	60.3	18.9	27.7	108.00	C80
Hodgkin lymphoma	22	0	0.7	0.0	0.9	0.9	1.3	0.6	1.3	1.1	2.0	2.5	1.1	2.9	2.0	2.2	3.6	0.0	0.0	0.0	867.00	C81
Non Hodgkin lymphoma	67	0	2.8	1.6	2.7	1.8	1.3	1.7	1.9	5.1	4.0	2.5	7.8	5.9	12.3	15.1	3.6	7.5	56.8	27.7	287.00	C84
Myeloma	18	0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.7	0.0	4.4	8.2	2.2	10.7	7.5	37.8	27.7	723.00	C90
Leukaemia	22	0	0.7	1.6	0.9	1.8	0.7	0.0	1.3	0.6	0.7	0.0	2.2	5.9	0.0	2.2	0.0	0.0	56.8	27.7	1093.00	C92
Haematology other	8	0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.8	1.1	1.5	2.0	2.2	0.0	0.0	0.0	0.0	2080.00	C96

ASIAN FEMALES

Site	All ages	Unknown ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	27	0	0.0	0.0	0.0	86.8	0.0	95.7	0.0	164.5	115.7	149.1	201.5	70.3	203.5	103.6	0.0	894.4	471.6	1662.7	17	
All sites but c44	27	0	0.0	0.0	0.0	86.8	0.0	95.7	0.0	164.5	115.7	149.1	201.5	70.3	203.5	103.6	0.0	894.4	471.6	1662.7	17	
Oesophagus	1	0	0.0	0.0	0.0	0.0	0.0	31.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	628	C15
Colorectal	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	447.2	471.6	0.0		C18
Pancreas	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1662.7		C25
Breast	12	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	65.8	38.6	99.4	201.5	70.3	203.5	103.6	0.0	0.0	0.0	0.0	26	C50
Cervix	2	0	0.0	0.0	0.0	0.0	0.0	31.9	0.0	0.0	38.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	284	C53
Uterus	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	447.2	0.0	0.0		C54
Bladder	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	608	C67
Thyroid	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	608	C73
Primary site unknown	3	0	0.0	0.0	0.0	43.4	0.0	0.0	0.0	32.9	38.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	175	C80
Hodgkin lymphoma	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	403	C81
Non Hodgkin lymphoma	2	0	0.0	0.0	0.0	43.4	0.0	31.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	266	C84

BLACK FEMALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	1297	3	7.9	6.4	9.1	5.1	11.7	29.9	81.5	93.2	145.2	187.7	222.9	298.4	379.4	443.5	504.3	715.8	354.4	467.8	9	
All sites but C44	1245	3	7.2	6.4	9.1	5.1	10.9	29.2	76.5	90.8	140.2	180.0	217.9	283.8	371.0	416.2	487.5	663.8	330.8	436.6	9	
Lip	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.2		C00
Tongue	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	9570	C02
Mouth	5	0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	2.8	0.0	5.6	0.0	23.6	0.0	1967	C06
Salivary gland	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.0	0.0	1.7	2.1	0.0	3.9	0.0	0.0	0.0	0.0	2124	C07
Naso-Oropharynx	7	0	0.0	0.0	1.0	0.0	0.0	0.0	0.8	0.0	0.0	2.6	0.0	2.1	2.8	0.0	0.0	0.0	23.6	0.0	2153	C11
Oesophagus	24	0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	1.7	10.4	8.4	7.8	22.4	52.1	23.6	93.6	390	C15
Stomach	14	0	0.0	0.0	0.0	0.0	0.8	0.7	0.8	0.8	1.0	1.3	0.0	4.2	5.6	3.9	0.0	39.0	0.0	0.0	1053	C16
Small intestine	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12049	C17
Colorectal	40	0	0.0	0.0	0.0	0.0	0.0	1.4	0.8	0.8	6.0	3.9	8.3	10.4	19.5	31.1	11.2	0.0	0.0	0.0	214	C18
Anus	17	0	0.0	0.0	0.0	0.0	0.0	1.4	1.6	3.9	1.0	3.9	3.3	0.0	0.0	0.0	5.6	13.0	0.0	0.0	965	C21
Liver & Bile duct	17	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	2.0	5.1	5.0	4.2	0.0	3.9	11.2	13.0	0.0	0.0	607	C22
Pancreas	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	6.7	0.0	5.6	3.9	0.0	0.0	0.0	0.0	1104	C25
Larynx	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	5.6	0.0	0.0	13.0	0.0	0.0	2608	C32
Lung	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	6.3	5.6	3.9	16.8	0.0	0.0	0.0	558	C34
Bone	7	0	0.8	0.0	0.0	1.0	0.0	0.0	1.6	0.0	2.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2806	C41
Melanoma	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	7.8	0.0	13.0	0.0	31.2	2119	C43
Skin other	9	0	0.8	0.0	0.0	0.0	0.8	0.7	0.0	0.0	0.0	1.3	0.0	6.3	0.0	7.8	0.0	0.0	0.0	0.0	1138	C44
SCC of skin	13	0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.8	2.0	2.6	0.0	0.0	2.8	7.8	0.0	13.0	0.0	31.2	1088	C44
BCC	30	0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	1.6	3.0	3.9	5.0	8.4	5.6	11.7	16.8	39.0	23.6	0.0	344	C44
Kaposi Sarcoma	34	0	0.0	0.0	1.0	0.0	1.6	7.6	7.4	2.3	5.0	1.3	1.7	0.0	0.0	3.9	0.0	0.0	0.0	0.0	629	C46
Connective tissue	8	0	0.8	0.0	0.0	0.0	0.8	0.0	0.0	0.8	0.0	1.3	0.0	6.3	0.0	0.0	5.6	0.0	0.0	0.0	1291	C49
Breast	297	2	0.0	0.0	0.0	0.0	2.3	3.5	15.6	22.7	39.1	54.0	54.9	70.9	75.3	81.7	134.5	221.3	47.3	124.8	37	C50
Vulva	21	0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	5.5	4.0	5.1	1.7	0.0	2.8	0.0	0.0	13.0	0.0	0.0	929	C51
Vagina	3	0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	2.8	3.9	0.0	0.0	0.0	0.0	2714	C52
Cervix	388	1	0.0	0.0	0.0	0.0	0.0	5.6	30.4	29.7	62.1	73.3	68.2	89.7	103.2	112.8	123.3	130.1	94.5	31.2	29	C53

Uterus	68	0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.0	2.6	3.3	16.7	47.4	62.2	78.4	39.0	23.6	93.6	95	C54
Ovary	26	0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.8	1.0	2.6	11.6	4.2	11.2	11.7	11.2	13.0	0.0	31.2	360	C56
Other specified	9	0	0.0	0.0	0.0	1.0	0.8	0.0	0.8	0.0	0.0	3.9	1.7	4.2	0.0	0.0	0.0	0.0	0.0	0.0	1624	C63
Kidney	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	3.9	0.0	13.0	0.0	0.0	3345	C64
Bladder	10	0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.0	0.0	0.0	3.3	2.1	2.8	7.8	11.2	0.0	0.0	0.0	697	C67
Eye	14	0	0.8	0.0	0.0	0.0	0.8	0.7	3.3	1.6	0.0	3.9	1.7	0.0	2.8	0.0	0.0	0.0	0.0	0.0	1297	C69
Brain, CNS	5	0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	2.1	2.8	0.0	0.0	0.0	0.0	0.0	2191	C71
Thyroid	15	0	0.0	0.0	1.0	0.0	0.0	0.7	1.6	1.6	0.0	2.6	1.7	2.1	5.6	3.9	5.6	13.0	0.0	0.0	760	C73
Endocrine	3	0	0.8	0.9	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7327	C74
Ill defined	9	0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.8	1.0	0.0	3.3	2.1	2.8	3.9	0.0	0.0	23.6	0.0	1342	C76
Primary site unknown	80	0	0.8	0.0	0.0	0.0	0.0	2.1	2.5	7.0	2.0	3.9	15.0	25.0	36.3	42.8	44.8	65.1	23.6	0.0	110	C80
Hodgkin lymphoma	16	0	0.8	0.0	1.0	1.0	0.8	0.7	0.8	1.6	3.0	2.6	1.7	2.1	2.8	0.0	0.0	0.0	0.0	0.0	1064	C81
Non Hodgkin lymphoma	39	0	2.4	1.8	3.0	0.0	1.6	1.4	1.6	7.0	4.0	2.6	6.7	2.1	5.6	7.8	0.0	0.0	23.6	0.0	421	C84
Myeloma	10	0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	2.6	0.0	4.2	8.4	3.9	0.0	13.0	0.0	0.0	1016	C90
Leukaemia	13	0	0.0	1.8	1.0	1.0	0.8	0.0	1.6	0.8	1.0	0.0	1.7	4.2	0.0	0.0	0.0	0.0	23.6	0.0	1436	C92
Haematology other	6	0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.8	1.0	1.3	1.7	0.0	2.8	0.0	0.0	0.0	0.0	0.0	2370	C96

COLOURED FEMALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	37	0	0.0	0.0	0.0	98.3	0.0	0.0	61.2	38.0	0.0	254.0	148.9	204.4	598.3	111.3	172.4	266.2	0.0	489.4	12	
All sites but C44	35	0	0.0	0.0	0.0	98.3	0.0	0.0	61.2	38.0	0.0	254.0	148.9	204.4	531.8	55.6	172.4	266.2	0.0	489.4	13	
Colorectal	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.8	0.0	51.1	66.5	0.0	0.0	0.0	0.0	0.0	134	C18
Liver & Bile duct	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	630	C22
Pancreas	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.5	0.0	0.0	0.0	0.0	0.0	301	C25
Lung	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	266.2	0.0	0.0		C34
Melanoma	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	489.4	1054	C43
BCC	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.5	0.0	0.0	0.0	0.0	0.0	301	C44
SCC of skin	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	55.6	0.0	0.0	0.0	0.0	360	C44
Breast	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	95.2	74.4	153.3	132.9	55.6	0.0	0.0	0.0	0.0	40	C50
Cervix	7	0	0.0	0.0	0.0	0.0	0.0	0.0	30.6	19.0	0.0	63.5	37.2	0.0	66.5	0.0	172.4	0.0	0.0	0.0	52	C53
Uterus	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.5	0.0	0.0	0.0	0.0	0.0	301	C54
Ovary	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	37.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	538	C56
Other specified	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	630	C63
Thyroid	1	0	0.0	0.0	0.0	0.0	0.0	0.0	30.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	654	C73
Primary site unknown	3	0	0.0	0.0	0.0	32.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	132.9	0.0	0.0	0.0	0.0	0.0	121	C80
Non Hodgkin lymphoma	1	0	0.0	0.0	0.0	32.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	611	C84
Leukaemia	1	0	0.0	0.0	0.0	32.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	611	C92

WHITE FEMALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	1080	4	35.9	9.2	0.0	0.0	28.9	58.8	164.3	131.6	286.9	265.0	447.4	681.4	1004.2	868.2	1458.4	1423.5	1837.6	1919.3	4	
All sites but C44	703	4	26.9	9.2	0.0	0.0	21.7	45.8	142.9	110.5	221.7	189.3	341.7	503.6	660.1	642.5	844.3	744.6	987.7	839.7	6	
Lip	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	0.0	0.0	2850	C00
Tongue	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.2	11.9	0.0	5.8	0.0	0.0	0.0	0.0	839	C02
Mouth	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.0	5.8	8.5	10.9	0.0	30.0	988	C06
Salivary gland	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.0	0.0		C07
Naso-Oropharynx	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	5.8	8.5	10.9	0.0	0.0	938	C11
Oesophagus	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.9	14.0	11.6	0.0	0.0	0.0	0.0	534	C15
Stomach	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	6.2	0.0	0.0	11.6	8.5	0.0	23.0	0.0	610	C16
Small intestine	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	8.5	0.0	0.0	0.0	1287	C17
Colorectal	59	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	16.2	18.6	23.7	77.3	52.1	85.3	87.6	206.7	90.0	72	C18
Anus	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.0	0.0	0.0	0.0	7.0	5.8	0.0	0.0	0.0	0.0	774	C21
Liver & Bile duct	15	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	14.0	23.1	34.1	32.8	0.0	30.0	259	C22
Pancreas	22	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	5.4	6.2	17.8	14.0	17.4	59.7	10.9	23.0	60.0	158	C25
Larynx	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.0	10.9	0.0	0.0	3697	C32
Lung	54	1	0.0	0.0	0.0	0.0	0.0	6.5	0.0	5.3	6.5	0.0	31.1	47.4	35.1	57.9	102.3	87.6	68.9	30.0	69	C34
Bone	2	0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1613	C41
Melanoma	35	0	0.0	0.0	0.0	0.0	0.0	13.1	14.3	5.3	19.6	5.4	18.6	11.9	28.1	28.9	25.6	32.8	68.9	90.0	118	C43
Skin other	7	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	21.1	0.0	0.0	21.9	23.0	0.0	756	C44
BCC	259	0	0.0	0.0	0.0	0.0	7.2	13.1	21.4	21.0	58.7	59.5	93.2	154.1	280.9	144.7	417.9	361.4	482.4	599.8	16	C44
SCC of skin	111	0	9.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	10.8	12.4	23.7	42.1	81.0	196.2	295.6	344.5	479.8	53	C44
Mesothelioma	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.4	8.5	10.9	0.0	0.0	773	C45
Kaposi Sarcoma	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.2	0.0	0.0	0.0	0.0	0.0	0.0	60.0	3221	C46
Connective tissue	2	0	9.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.5	0.0	0.0	0.0	1143	C49
Breast	231	0	0.0	0.0	0.0	0.0	0.0	13.1	50.0	47.4	97.8	108.2	136.7	154.1	217.7	185.2	221.7	229.9	275.6	239.9	17	C50
Vulva	4	0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	5.9	7.0	0.0	0.0	10.9	0.0	0.0	996	C51
Vagina	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3697	C52

Cervix	46	0	0.0	0.0	0.0	0.0	0.0	0.0	14.3	31.6	6.5	21.6	37.3	47.4	42.1	28.9	25.6	32.8	23.0	30.0	79	C53
Uterus	20	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	12.4	23.7	21.1	17.4	8.5	43.8	45.9	0.0	227	C54
Ovary	19	0	0.0	0.0	0.0	0.0	7.2	0.0	0.0	0.0	0.0	0.0	6.2	11.9	7.0	40.5	25.6	21.9	23.0	30.0	204	C56
Other specified	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.0	0.0	0.0	5.9	35.1	0.0	17.1	10.9	0.0	0.0	282	C63
Kidney	8	0	0.0	9.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.9	14.0	5.8	8.5	10.9	0.0	0.0	405	C64
Bladder	13	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.8	7.0	11.6	25.6	32.8	23.0	0.0	323	C67
Brain, CNS	16	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	12.4	23.7	7.0	17.4	17.1	10.9	45.9	30.0	238	C71
Thyroid	12	0	0.0	0.0	0.0	0.0	7.2	6.5	0.0	5.3	19.6	5.4	6.2	0.0	0.0	11.6	17.1	0.0	0.0	0.0	254	C73
Endocrine	5	0	0.0	0.0	0.0	0.0	0.0	0.0	14.3	0.0	0.0	0.0	6.2	0.0	0.0	0.0	17.1	0.0	0.0	0.0	533	C74
Ill defined	3	0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	7.0	0.0	8.5	0.0	0.0	0.0	882	C76
Primary site unknown	34	0	0.0	0.0	0.0	0.0	0.0	6.5	14.3	0.0	13.0	10.8	6.2	17.8	49.2	34.7	51.2	32.8	0.0	30.0	99	C80
Hodgkin lymphoma	5	0	0.0	0.0	0.0	0.0	7.2	0.0	7.1	0.0	0.0	0.0	0.0	5.9	0.0	5.8	8.5	0.0	0.0	0.0	578	C81
Non Hodgkin lymphoma	25	0	9.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	13.0	5.4	18.6	17.8	28.1	28.9	8.5	10.9	45.9	30.0	147	C84
Myeloma	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	7.0	0.0	25.6	0.0	45.9	30.0	519	C90
Leukaemia	8	0	9.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.2	11.9	0.0	5.8	0.0	0.0	45.9	30.0	610	C92
Haematology other	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.0	5.8	0.0	0.0	0.0	0.0	1707	C96

ALL MALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	2245	2	10.5	7.2	11.4	15.7	10.9	12.6	21.8	51.6	70.3	135.1	235.1	391.6	604.8	745.4	949.2	1246.0	1356.9	1116.8	7	
All sites but C44	1540	2	10.5	7.2	10.5	15.7	10.9	11.4	19.0	39.3	44.2	98.6	160.5	275.7	466.0	524.6	584.4	740.7	722.9	543.7	9	
Lip	6	0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.8	1.0	1.2	0.0	1.9	0.0	3.2	0.0	0.0	0.0	2278	C00
Tongue	14	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	2.5	4.4	7.6	6.6	0.0	5.7	0.0	0.0	915	C02
Mouth	14	0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	3.9	1.2	0.0	7.6	4.4	6.5	0.0	0.0	0.0	826	C06
Salivary gland	7	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.0	0.0	1.5	0.0	6.6	3.2	0.0	0.0	0.0	1552	C07
Naso-Oropharynx	27	0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	0.6	0.0	2.0	3.7	8.8	9.5	4.4	9.7	17.2	0.0	0.0	501	C11
Oesophagus	65	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	7.5	13.2	30.4	35.0	16.1	28.7	11.1	29.4	187	C15
Stomach	27	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	2.0	5.0	7.3	7.6	4.4	9.7	11.5	0.0	29.4	528	C16
Small intestine	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	4.4	0.0	0.0	3.2	0.0	0.0	0.0	2158	C17
Colorectal	121	1	0.0	0.0	0.0	0.0	0.7	0.6	0.7	3.2	3.3	8.9	19.9	20.5	41.8	35.0	25.8	57.4	133.5	44.1	125	C18
Anus	15	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	1.6	4.9	1.2	0.0	1.9	6.6	3.2	0.0	0.0	0.0	960	C21
Liver & Bile duct	32	0	0.0	0.0	0.0	0.0	0.0	0.6	1.4	0.6	2.5	1.0	3.7	8.8	7.6	10.9	6.5	11.5	11.1	14.7	459	C22
Pancreas	28	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.8	0.0	6.2	4.4	7.6	15.3	9.7	5.7	33.4	0.0	448	C25
Larynx	16	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.0	2.5	4.4	9.5	2.2	9.7	0.0	0.0	0.0	668	C32
Lung	82	0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.6	3.3	2.0	7.5	16.1	24.7	35.0	35.5	51.7	55.6	29.4	159	C34
Bone	15	0	0.0	0.0	0.9	0.9	0.7	0.6	0.7	0.6	1.6	1.0	1.2	0.0	3.8	4.4	3.2	0.0	0.0	0.0	1019	C41
Melanoma	73	0	0.0	0.0	0.0	0.0	0.7	0.0	1.4	1.9	1.6	4.9	2.5	8.8	26.6	17.5	25.8	57.4	77.8	73.5	218	C43
SCC of skin	191	0	0.0	0.0	0.9	0.0	0.0	0.6	0.7	0.6	5.7	10.9	17.4	22.0	19.0	45.9	119.4	178.0	266.9	249.8	83	C44
BCC	489	0	0.0	0.0	0.0	0.0	0.0	0.6	2.1	9.0	17.2	22.7	54.7	90.9	116.0	170.5	242.1	310.1	344.8	323.3	28	C44
Skin other	25	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	3.3	3.0	2.5	2.9	3.8	4.4	3.2	17.2	22.2	0.0	781	C44
Mesothelioma	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	2.2	9.7	11.5	0.0	14.7	1525	C45
Kaposi Sarcoma	40	0	0.7	0.0	0.0	0.9	1.4	1.2	4.2	3.9	1.6	6.9	2.5	4.4	0.0	4.4	12.9	11.5	0.0	0.0	446	C46
Connective tissue	21	0	0.7	0.8	0.0	0.0	0.7	0.6	0.0	0.6	2.5	1.0	6.2	1.5	3.8	4.4	3.2	5.7	0.0	0.0	771	C49
Breast	15	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	2.5	1.5	5.7	4.4	9.7	5.7	11.1	0.0	800	C50
Cervix	2	0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15152	C53
Ovary	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31251	C56

Penis	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	3.0	1.2	0.0	1.9	0.0	0.0	5.7	0.0	0.0	2340	C60
Prostate	476	0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.6	2.5	12.8	33.6	96.8	190.2	212.0	268.0	292.9	222.4	205.7	25	C61
Testis	9	0	0.7	0.0	0.0	0.0	0.0	0.6	3.5	0.6	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	2618	C62
Other specified	18	0	0.7	0.0	0.0	0.9	0.0	0.0	0.0	0.6	0.0	0.0	2.5	4.4	3.8	10.9	0.0	17.2	0.0	0.0	840	C63
Kidney	13	0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	5.9	1.9	0.0	0.0	5.7	11.1	0.0	1595	C64
Bladder	46	0	0.0	0.0	0.0	0.9	0.0	0.0	0.7	0.0	0.8	3.9	3.7	5.9	7.6	15.3	19.4	45.9	44.5	44.1	344	C67
Eye	9	0	1.4	0.0	0.0	0.0	0.0	0.6	0.0	1.3	0.0	0.0	2.5	1.5	1.9	0.0	0.0	0.0	0.0	0.0	2186	C69
Brain, CNS	32	1	0.7	1.6	0.0	1.7	0.0	1.8	0.7	1.3	0.8	1.0	0.0	7.3	5.7	6.6	6.5	17.2	22.2	29.4	561	C71
Thyroid	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.0	0.0	1.5	3.8	2.2	0.0	0.0	0.0	0.0	2201	C73
Endocrine	5	0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.0	1.2	1.5	0.0	0.0	0.0	0.0	0.0	0.0	3892	C74
Ill defined	13	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.8	1.0	1.2	1.5	5.7	8.7	0.0	0.0	0.0	0.0	988	C76
Primary site unknown	115	0	0.7	0.0	2.6	0.9	1.4	0.0	1.4	3.2	5.7	12.8	11.2	20.5	20.9	52.5	45.2	34.5	22.2	14.7	112	C80
Hodgkin lymphoma	34	0	0.0	1.6	4.4	3.5	1.4	2.4	0.0	3.2	0.0	3.0	5.0	0.0	3.8	2.2	3.2	5.7	0.0	0.0	595	C81
Burkitt lymphoma	2	0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11765	C83
Non Hodgkin lymphoma	66	0	0.7	1.6	0.9	6.1	0.7	0.0	0.7	5.8	4.1	5.9	9.9	8.8	9.5	6.6	19.4	5.7	33.4	14.7	248	C84
Myeloma	23	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.8	1.0	2.5	5.9	5.7	2.2	16.1	11.5	33.4	0.0	574	C90
Leukaemia	27	0	1.4	0.8	0.9	0.0	0.7	0.6	0.7	0.6	1.6	3.9	6.2	4.4	3.8	0.0	0.0	17.2	0.0	0.0	779	C92
Haematology other	5	0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	1.6	0.0	1.2	0.0	1.9	0.0	0.0	0.0	0.0	0.0	3664	C96

ASIAN MALES																						
Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	28	0	0.0	0.0	49.0	0.0	0.0	35.8	26.7	66.4	32.4	37.9	110.5	201.4	264.5	743.8	597.3	987.7	0.0	0.0	10	
All sites but C44	25	0	0.0	0.0	49.0	0.0	0.0	35.8	26.7	44.3	32.4	37.9	110.5	201.4	264.5	619.8	398.2	987.7	0.0	0.0	11	
Lip	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	618	C00
Mouth	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	37.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	528	C06
Naso-Oropharynx	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	162	C11
Oesophagus	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	329.2	0.0	0.0		C15
Colorectal	3	0	0.0	0.0	0.0	0.0	0.0	0.0	26.7	0.0	0.0	0.0	0.0	67.2	88.2	0.0	0.0	0.0	0.0	0.0	110	C18
Liver & Bile duct	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	55.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	362	C22
Pancreas	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	55.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	362	C25
Lung	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	162	C34
Melanoma	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	329.2	0.0	0.0		C43
BCC	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.1	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	137	C44
SCC of skin	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	199.1	0.0	0.0	0.0	101	C44
Prostate	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	88.2	247.9	398.2	0.0	0.0	0.0	28	C61
Testis	1	0	0.0	0.0	0.0	0.0	0.0	35.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	559	C62
Kidney	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.2	0.0	0.0	0.0	0.0	0.0	0.0	298	C64
Endocrine	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	904	C74
Primary site unknown	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.2	88.2	124.0	0.0	329.2	0.0	0.0	72	C80
Hodgkin lymphoma	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	904	C81
Non Hodgkin lymphoma	1	0	0.0	0.0	49.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	409	C84

BLACK MALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	831	0	11.1	7.1	9.3	13.8	10.5	9.4	14.7	33.4	42.9	64.2	124.8	226.8	392.5	406.2	446.7	711.7	496.1	584.2	12	
All sites but C44	753	0	11.1	7.1	8.3	13.8	10.5	8.8	14.0	29.4	33.2	56.7	111.8	210.3	365.7	366.3	389.3	660.9	460.6	584.2	13	
Tongue	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	4.1	0.0	3.6	0.0	17.0	0.0	0.0	1878	C02
Mouth	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	8.9	7.3	6.4	0.0	0.0	0.0	811	C06
Salivary gland	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.1	0.0	2.1	0.0	3.6	0.0	0.0	0.0	0.0	2692	C07
Naso-Oropharynx	17	0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.7	0.0	2.1	4.3	8.3	8.9	3.6	6.4	17.0	0.0	0.0	570	C11
Oesophagus	36	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	5.8	10.3	23.8	39.9	6.4	17.0	35.4	97.4	224	C15
Stomach	15	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	4.3	8.3	8.9	0.0	12.8	0.0	0.0	0.0	552	C16
Small intestine	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	6.2	0.0	0.0	0.0	0.0	0.0	0.0	2561	C17
Colorectal	40	0	0.0	0.0	0.0	0.0	0.8	0.6	0.0	0.7	2.4	4.3	8.7	10.3	14.9	25.4	6.4	33.9	106.3	48.7	269	C18
Anus	13	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	1.6	5.3	1.5	0.0	3.0	7.3	0.0	0.0	0.0	0.0	998	C21
Liver & Bile duct	16	0	0.0	0.0	0.0	0.0	0.0	0.6	1.5	0.7	2.4	0.0	2.9	4.1	5.9	7.3	6.4	0.0	0.0	0.0	630	C22
Pancreas	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	2.1	3.0	10.9	0.0	0.0	35.4	0.0	1064	C25
Larynx	15	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.1	1.5	6.2	14.9	3.6	19.1	0.0	0.0	0.0	425	C32
Lung	25	0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.7	3.2	0.0	4.3	6.2	17.8	10.9	6.4	17.0	35.4	0.0	393	C34
Bone	10	0	0.0	0.0	0.0	1.1	0.8	0.6	0.7	0.7	0.8	1.1	0.0	0.0	3.0	7.3	0.0	0.0	0.0	0.0	1255	C41
Melanoma	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.0	0.0	0.0	8.9	3.6	0.0	17.0	35.4	48.7	1426	C43
BCC	40	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	4.8	2.1	5.8	8.3	23.8	29.0	38.3	0.0	35.4	0.0	178	C44
SCC of skin	26	0	0.0	0.0	1.0	0.0	0.0	0.6	0.7	0.7	3.2	3.2	5.8	8.3	0.0	7.3	19.1	33.9	0.0	0.0	401	C44
Skin other	12	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	1.6	2.1	1.5	0.0	3.0	3.6	0.0	17.0	0.0	0.0	1382	C44
Mesothelioma	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	17.0	0.0	0.0	3135	C45
Kaposi Sarcoma	36	0	0.8	0.0	0.0	1.1	1.5	1.3	4.4	3.3	1.6	5.3	2.9	6.2	0.0	7.3	25.5	17.0	0.0	0.0	327	C46
Connective tissue	14	0	0.8	0.9	0.0	0.0	0.8	0.6	0.0	0.0	1.6	1.1	5.8	2.1	0.0	3.6	6.4	0.0	0.0	0.0	847	C49
Breast	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	2.9	0.0	5.9	0.0	6.4	0.0	0.0	0.0	1258	C50
Penis	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	3.2	1.5	0.0	3.0	0.0	0.0	0.0	0.0	0.0	1989	C60

Prostate	231	0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.7	0.0	4.3	17.4	90.7	160.6	159.6	217.0	423.7	177.2	340.8	31	C61
Testis	3	0	0.8	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	3876	C62
Other specified	8	0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.5	2.1	5.9	3.6	0.0	17.0	0.0	0.0	1375	C63
Kidney	5	0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	3.0	0.0	0.0	0.0	0.0	0.0	2700	C64
Bladder	7	0	0.0	0.0	0.0	1.1	0.0	0.0	0.7	0.0	0.8	0.0	0.0	2.1	3.0	3.6	0.0	0.0	35.4	0.0	1775	C67
Eye	9	0	1.6	0.0	0.0	0.0	0.0	0.6	0.0	1.3	0.0	0.0	2.9	2.1	3.0	0.0	0.0	0.0	0.0	0.0	1743	C69
Brain, CNS	8	0	0.8	1.8	0.0	1.1	0.0	1.3	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	1676	C71
Thyroid	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	5.9	3.6	0.0	0.0	0.0	0.0	1719	C73
Endocrine	2	0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8548	C74
Ill defined	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.8	1.1	1.5	2.1	8.9	7.3	0.0	0.0	0.0	0.0	874	C76
Primary site unknown	69	0	0.8	0.0	3.1	1.1	1.5	0.0	1.5	3.3	5.7	8.6	13.1	14.4	23.8	32.6	19.1	50.8	0.0	48.7	156	C80
Hodgkin lymphoma	27	0	0.0	1.8	4.1	2.1	1.5	2.5	0.0	2.0	0.0	3.2	4.3	0.0	5.9	3.6	6.4	0.0	0.0	0.0	533	C81
Burkitt lymphoma	2	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10870	C83
Non Hodgkin lymphoma	42	0	0.8	0.9	0.0	6.4	0.8	0.0	0.7	5.3	4.0	4.3	7.3	6.2	8.9	3.6	19.1	0.0	0.0	0.0	293	C84
Myeloma	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	1.1	2.9	6.2	0.0	0.0	6.4	0.0	0.0	0.0	1110	C90
Leukaemia	20	0	1.6	0.9	0.0	0.0	0.0	0.6	0.7	0.7	0.8	4.3	5.8	4.1	5.9	0.0	0.0	17.0	0.0	0.0	785	C92
Haematology other	3	0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.8	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6645	C96

COLOURED MALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	30	0	0.0	0.0	0.0	32.0	0.0	0.0	30.6	20.4	26.7	92.0	46.7	287.9	941.4	437.9	195.1	1316.6	0.0	0.0	10	
All sites but C44	27	0	0.0	0.0	0.0	32.0	0.0	0.0	30.6	20.4	26.7	92.0	46.7	287.9	823.8	350.3	0.0	1316.6	0.0	0.0	12	
Tongue	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.7	0.0	0.0	0.0	0.0	0.0	170	C02
Oesophagus	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.7	0.0	0.0	0.0	0.0	0.0	170	C15
Stomach	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.7	0.0	0.0	0.0	0.0	0.0	170	C16
Colorectal	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	61.3	46.7	48.0	235.4	0.0	0.0	0.0	0.0	0.0	52	C18
Pancreas	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	96.0	0.0	0.0	0.0	0.0	0.0	0.0	209	C25
Melanoma	1	0	0.0	0.0	0.0	0.0	0.0	0.0	30.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	654	C43
BCC	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.7	87.6	195.1	0.0	0.0	0.0	50	C44
Kaposi Sarcoma	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	653	C46
Prostate	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	48.0	235.4	0.0	0.0	658.3	0.0	0.0	71	C61
Other specified	2	0	0.0	0.0	0.0	32.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	87.6	0.0	0.0	0.0	0.0	168	C63
Bladder	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	87.6	0.0	0.0	0.0	0.0	229	C67
Primary site unknown	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	48.0	0.0	175.1	0.0	0.0	0.0	0.0	90	C80
Hodgkin lymphoma	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	983	C81
Non Hodgkin lymphoma	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	48.0	0.0	0.0	0.0	658.3	0.0	0.0	417	C84
Haematology other	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	750	C96

WHITE MALES																						
Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74	ICD10
All sites	1356	2	8.8	9.4	26.7	29.0	14.3	36.8	62.5	142.5	168.9	371.3	602.9	914.0	1316.2	1284.8	1952.4	2464.2	4607.9	4413.6	3	
All sites but C44	735	2	8.8	9.4	26.7	29.0	14.3	29.5	41.7	76.7	59.9	218.7	295.4	475.5	842.4	766.2	1047.2	1232.1	2218.6	1724.1	6	
Lip	5	0	0.0	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	5.1	6.0	0.0	7.5	0.0	8.9	0.0	0.0	0.0	574	C00
Tongue	7	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	6.2	22.6	11.8	0.0	0.0	0.0	0.0	435	C02
Mouth	5	0	0.0	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	5.1	6.0	0.0	7.5	0.0	8.9	0.0	0.0	0.0	574	C06
Salivary gland	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.8	8.9	0.0	0.0	0.0	969	C07
Naso-Oropharynx	9	0	0.0	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	0.0	12.4	15.0	0.0	17.8	29.0	0.0	0.0	381	C11
Oesophagus	27	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.2	12.1	24.7	52.7	29.5	35.5	43.5	0.0	0.0	122	C15
Stomach	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.2	6.0	6.2	0.0	11.8	8.9	29.0	0.0	137.9	465	C16
Small intestine	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.9	0.0	0.0	0.0	2255	C17
Colorectal	72	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.9	5.4	15.3	54.3	43.2	105.3	53.0	62.1	116.0	384.0	137.9	56	C18
Anus	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	8.9	0.0	0.0	0.0	1356	C21
Liver & Bile duct	15	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	24.7	15.0	17.7	8.9	29.0	42.7	69.0	281	C22
Pancreas	17	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	5.4	0.0	12.1	0.0	22.6	23.6	26.6	14.5	85.3	0.0	209	C25
Larynx	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3317	C32
Lung	56	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.2	18.1	49.4	52.7	70.7	88.8	116.0	170.7	137.9	70	C34
Bone	5	0	0.0	0.0	8.9	0.0	0.0	0.0	0.0	0.0	5.4	0.0	6.0	0.0	7.5	0.0	8.9	0.0	0.0	0.0	545	C41
Melanoma	62	0	0.0	0.0	0.0	0.0	7.1	0.0	6.9	11.0	5.4	25.4	12.1	37.1	82.7	41.3	71.0	116.0	256.0	275.9	67	C43
Skin other	13	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.9	5.1	6.0	12.4	7.5	5.9	8.9	29.0	85.3	0.0	354	C44
BCC	444	0	0.0	0.0	0.0	0.0	0.0	7.4	20.8	65.8	81.7	106.8	241.1	358.2	391.1	400.8	603.5	782.8	1280.0	1517.2	9	C44
SCC of skin	164	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.3	40.7	60.3	67.9	75.2	112.0	292.9	420.4	1024.0	1172.3	31	C44
Mesothelioma	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	5.9	17.8	14.5	0.0	69.0	675	C45
Kaposi Sarcoma	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	5.1	0.0	0.0	0.0	0.0	0.0	14.5	0.0	0.0	1893	C46
Connective tissue	7	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	5.4	0.0	6.0	0.0	15.0	5.9	0.0	14.5	0.0	0.0	528	C49
Breast	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	6.2	7.5	11.8	17.8	14.5	42.7	0.0	411	C50

Penis	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.5	0.0	0.0		C60
Prostate	236	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.3	45.8	90.4	129.7	323.4	300.6	417.1	362.4	640.0	482.7	16	C61
Testis	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.8	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	602	C62
Other specified	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	12.4	0.0	17.7	0.0	29.0	0.0	0.0	555	C63
Kidney	7	0	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.2	0.0	12.4	0.0	0.0	0.0	14.5	42.7	0.0	638	C64
Bladder	38	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.3	18.1	18.5	22.6	29.5	53.3	116.0	128.0	206.9	124	C67
Brain, CNS	24	1	0.0	0.0	0.0	7.3	0.0	7.4	6.9	5.5	5.4	5.1	0.0	30.9	22.6	17.7	8.9	43.5	85.3	137.9	171	C71
Thyroid	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1893	C73
Endocrine	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	6.2	0.0	0.0	0.0	0.0	0.0	0.0	1775	C74
Ill defined	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.8	0.0	0.0	0.0	0.0	1697	C76
Primary site unknown	39	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.4	0.0	30.9	15.0	70.7	97.6	29.0	85.3	0.0	84	C80
Hodgkin lymphoma	5	0	0.0	0.0	8.9	14.5	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.0	14.5	0.0	0.0	680	C81
Non Hodgkin lymphoma	21	0	0.0	9.4	0.0	7.3	0.0	0.0	0.0	5.5	0.0	10.2	18.1	12.4	15.0	11.8	26.6	0.0	128.0	69.0	173	C84
Myeloma	14	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.2	22.6	5.9	35.5	29.0	128.0	0.0	286	C90
Leukaemia	7	0	0.0	0.0	8.9	0.0	7.1	0.0	0.0	0.0	5.4	0.0	6.0	6.2	0.0	0.0	0.0	29.0	0.0	0.0	594	C92
Haematology other	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.0	0.0	0.0	0.0	0.0	2660	C96

Frequency of Cancer by Age Group

ALL FEMALES																					
Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	2441	7	14	8	9	10	19	55	124	151	192	206	213	263	290	267	188	96	81	262	ALL
All sites but C44	2010	7	12	8	9	10	17	52	115	144	177	186	193	226	237	220	122	58	44	187	ALLbC44
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	C00
Tongue	5	0	0	0	0	0	0	0	0	0	0	0	1	3	0	1	0	0	0	0	C02
Mouth	10	0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	1	1	2	C06
Salivary gland	6	0	0	0	0	0	0	0	0	1	1	0	1	1	0	1	0	1	0	0	C07
Naso-Oropharynx	11	0	0	0	1	0	0	0	1	0	0	2	0	1	2	1	1	1	0	1	C11
Oesophagus	31	0	0	0	0	0	0	2	0	0	0	0	1	7	5	4	4	1	3	4	C15
Stomach	20	0	0	0	0	0	1	1	1	1	2	1	1	2	2	3	3	1	0	1	C16
Small intestine	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	C17
Colorectal	104	2	0	0	0	0	0	2	1	2	6	7	8	10	19	17	9	10	3	12	C18
Anus	21	0	0	0	0	0	0	2	2	5	3	3	2	0	1	1	1	0	0	1	C21
Liver & Bile duct	33	0	0	0	0	0	0	0	0	2	2	5	3	3	2	5	4	0	1	6	C22
Pancreas	33	0	0	0	0	0	0	0	0	0	3	1	5	3	5	4	1	1	3	7	C25
Larynx	6	0	0	0	0	0	0	0	0	0	0	1	0	1	2	0	2	0	0	0	C32
Lung	66	1	0	0	0	0	0	1	0	1	1	0	7	11	7	11	9	3	1	15	C34
Bone	9	0	1	0	0	1	0	0	3	1	2	0	1	0	0	0	0	0	0	0	C41
Melanoma	42	0	0	0	0	0	0	2	2	2	3	1	4	2	4	7	4	3	5	3	C43
SCC of skin	125	0	1	0	0	0	0	0	3	1	3	4	2	4	7	17	28	15	17	23	C44
BCC	290	0	0	0	0	0	1	2	6	6	12	14	18	30	43	28	36	22	20	52	C44
Skin other	16	0	1	0	0	0	1	1	0	0	0	2	0	3	3	2	2	1	0	0	C44
Mesothelioma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	1	C45
Kaposi Sarcoma	37	0	0	0	1	0	2	11	9	3	5	1	2	0	0	1	0	0	2	0	C46
Connective tissue	10	0	2	0	0	0	1	0	0	1	0	1	0	3	0	0	0	0	0	2	C49
Breast	551	2	0	0	0	0	3	7	26	40	55	67	60	64	62	55	38	14	12	50	C50

Vulva	25	0	0	0	0	0	0	0	4	7	4	4	1	1	2	0	2	0	0	0	C51
Vagina	4	0	0	0	0	0	0	1	0	0	0	1	0	0	1	1	0	0	0	0	C52
Cervix	443	1	0	0	0	0	0	9	40	45	64	63	48	51	44	34	13	5	2	26	C53
Uterus	90	0	0	0	0	0	0	0	1	1	1	2	4	12	21	19	8	3	3	15	C54
Ovary	46	0	0	0	0	0	1	1	1	1	1	2	9	4	5	10	3	1	2	5	C56
Other specified	21	0	0	0	0	1	1	0	1	0	2	4	1	3	5	0	1	0	0	2	C63
Kidney	11	0	0	1	0	0	0	0	0	0	0	0	0	3	2	2	2	0	0	1	C64
Bladder	24	0	0	0	0	0	0	1	1	1	0	0	2	4	2	4	3	1	0	5	C67
Eye	14	0	1	0	0	0	1	1	4	2	0	3	1	0	1	0	0	0	0	0	C69
Brain, CNS	21	1	0	1	0	0	0	0	0	0	1	0	4	5	2	3	1	2	1	2	C71
Thyroid	29	0	0	0	1	0	1	2	3	4	3	3	2	1	2	3	1	0	0	3	C73
Endocrine	8	0	1	1	1	0	0	0	2	0	0	0	1	0	0	0	0	0	0	2	C74
Ill defined	12	0	0	0	0	1	0	0	1	1	1	0	2	1	2	1	0	1	0	1	C76
Primary site unknown	120	0	1	0	0	2	0	4	5	10	5	5	10	15	22	17	8	1	1	14	C80
Hodgkin lymphoma	22	0	1	0	1	1	2	1	2	2	3	3	1	2	1	1	0	0	0	1	C81
Non Hodgkin lymphoma	67	0	4	2	3	2	2	3	3	9	6	3	7	4	6	7	1	3	1	1	C84
Myeloma	18	0	0	0	0	0	0	1	0	0	0	2	0	3	4	1	1	2	1	3	C90
Leukaemia	22	0	1	2	1	2	1	0	2	1	1	0	2	4	0	1	0	3	1	0	C92
Haematology other	8	0	0	1	0	0	0	0	0	1	1	1	1	1	1	1	0	0	0	0	C96

ASIAN FEMALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites but C44	27	0	0	0	0	2	0	3	0	5	3	3	3	1	2	1	2	1	1	0	ALLbC44
All sites	27	0	0	0	0	2	0	3	0	5	3	3	3	1	2	1	2	1	1	0	ALL
Oesophagus	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	C15
Colorectal	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	C18
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	C25
Breast	12	0	0	0	0	0	0	0	0	2	1	2	3	1	2	1	0	0	0	0	C50
Cervix	2	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	C53
Uterus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C54
Bladder	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	C67
Thyroid	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	C73
Primary site unknown	3	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	C80
Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	C81
Non Hodgkin lymphoma	2	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	C84

BLACK FEMALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	1297	3	10	7	9	5	15	43	99	119	145	146	134	143	136	114	55	15	15	90	ALL
All sites but C44	1245	3	9	7	9	5	14	42	93	116	140	140	131	136	133	107	51	14	14	87	ALLBC44
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	C00
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C02
Mouth	5	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	1	0	1	C06
Salivary gland	5	0	0	0	0	0	0	0	0	1	1	0	1	1	0	1	0	0	0	0	C07
Naso-Oropharynx	7	0	0	0	1	0	0	0	1	0	0	2	0	1	1	0	0	1	0	0	C11
Oesophagus	24	0	0	0	0	0	0	1	0	0	0	0	1	5	3	2	4	1	3	4	C15
Stomach	14	0	0	0	0	0	1	1	1	1	1	1	0	2	2	1	3	0	0	0	C16
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C17
Colorectal	40	0	0	0	0	0	0	2	1	1	6	3	5	5	7	8	0	0	0	2	C18
Anus	17	0	0	0	0	0	0	2	2	5	1	3	2	0	0	0	1	0	0	1	C21
Liver & Bile duct	17	0	0	0	0	0	0	0	0	2	2	4	3	2	0	1	1	0	0	2	C22
Pancreas	9	0	0	0	0	0	0	0	0	0	2	0	4	0	2	1	0	0	0	0	C25
Larynx	4	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	0	0	0	C32
Lung	11	0	0	0	0	0	0	0	0	0	0	0	2	3	2	1	0	0	0	3	C34
Bone	7	0	1	0	0	1	0	0	2	0	2	0	1	0	0	0	0	0	0	0	C41
Melanoma	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	1	0	1	0	C43
BCC	30	0	0	0	0	0	0	0	3	2	3	3	3	4	2	3	3	1	0	3	C44
SCC of skin	13	0	0	0	0	0	0	0	3	1	2	2	0	0	1	2	1	0	1	0	C44
Skin other	9	0	1	0	0	0	1	1	0	0	0	1	0	3	0	2	0	0	0	0	C44
Kaposi Sarcoma	34	0	0	0	1	0	2	11	9	3	5	1	1	0	0	1	0	0	0	0	C46
Connective tissue	8	0	1	0	0	0	1	0	0	1	0	1	0	3	0	0	0	0	0	1	C49
Breast	297	2	0	0	0	0	3	5	19	29	39	42	33	34	27	21	17	2	4	24	C50
Vulva	21	0	0	0	0	0	0	0	3	7	4	4	1	0	1	0	1	0	0	0	C51
Vagina	3	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	C52
Cervix	388	1	0	0	0	0	0	8	37	38	62	57	41	43	37	29	10	4	1	22	C53

Uterus	68	0	0	0	0	0	0	0	1	0	1	2	2	8	17	16	3	1	3	14	C54
Ovary	26	0	0	0	0	0	0	1	1	1	1	2	7	2	4	3	1	0	1	2	C56
Other specified	9	0	0	0	0	1	1	0	1	0	0	3	1	2	0	0	0	0	0	0	C63
Kidney	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	C64
Bladder	10	0	0	0	0	0	0	1	1	0	0	0	2	1	1	2	0	0	0	2	C67
Eye	14	0	1	0	0	0	1	1	4	2	0	3	1	0	1	0	0	0	0	0	C69
Brain, CNS	5	0	0	1	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0	0	C71
Thyroid	15	0	0	0	1	0	0	1	2	2	0	2	1	1	2	1	1	0	0	1	C73
Endocrine	3	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C74
Ill defined	9	0	0	0	0	1	0	0	0	1	1	0	2	1	1	1	0	1	0	0	C76
Primary site unknown	80	0	1	0	0	0	0	3	3	9	2	3	9	12	13	11	5	1	0	8	C80
Hodgkin lymphoma	16	0	1	0	1	1	1	1	1	2	3	2	1	1	1	0	0	0	0	0	C81
Non Hodgkin lymphoma	39	0	3	2	3	0	2	2	2	9	4	2	4	1	2	2	0	1	0	0	C84
Myeloma	10	0	0	0	0	0	0	1	0	0	0	2	0	2	3	1	1	0	0	0	C90
Leukaemia	13	0	0	2	1	1	1	0	2	1	1	0	1	2	0	0	0	1	0	0	C92
Haematology other	6	0	0	1	0	0	0	0	0	1	1	1	1	0	1	0	0	0	0	0	C96

COLOURED FEMALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	37	0	0	0	0	3	0	0	2	2	0	8	4	4	9	2	1	0	1	1	ALL
All sites but C44	35	0	0	0	0	3	0	0	2	2	0	8	4	4	8	1	1	0	1	1	ALLbC44
Colorectal	3	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	C18
Liver & Bile duct	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	C22
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C25
Lung	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C34
Melanoma	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	C43
BCC	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C44
SCC of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C44
Breast	11	0	0	0	0	0	0	0	0	0	0	3	2	3	2	1	0	0	0	0	C50
Cervix	7	0	0	0	0	0	0	0	1	1	0	2	1	0	1	0	0	0	0	1	C53
Uterus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C54
Ovary	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C56
Other specified	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	C63
Thyroid	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	C73
Primary site unknown	3	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0	0	0	0	0	C80
Non Hodgkin lymphoma	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C84
Leukaemia	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C92

WHITE FEMALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	1080	4	4	1	0	0	4	9	23	25	44	49	72	115	143	150	130	80	64	171	ALL
All sites but C44	703	4	3	1	0	0	3	7	20	21	34	35	55	85	94	111	68	43	28	99	ALLbC44
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C00
Tongue	4	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	0	0	0	0	C02
Mouth	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	1	1	C06
Salivary gland	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C07
Naso-Oropharynx	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	1	C11
Oesophagus	6	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	0	0	0	0	C15
Stomach	6	0	0	0	0	0	0	0	0	0	1	0	1	0	0	2	0	1	0	1	C16
Small intestine	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	C17
Colorectal	59	2	0	0	0	0	0	0	0	1	0	3	3	4	11	9	8	9	3	10	C18
Anus	4	0	0	0	0	0	0	0	0	0	2	0	0	0	1	1	0	0	0	0	C21
Liver & Bile duct	15	0	0	0	0	0	0	0	0	0	0	0	0	1	2	4	3	0	1	4	C22
Pancreas	22	0	0	0	0	0	0	0	0	0	1	1	1	3	2	3	1	1	2	7	C25
Larynx	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	C32
Lung	54	1	0	0	0	0	0	1	0	1	1	0	5	8	5	10	8	3	1	12	C34
Bone	2	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	C41
Melanoma	35	0	0	0	0	0	0	2	2	1	3	1	3	2	4	5	3	3	3	3	C43
Skin other	7	0	0	0	0	0	0	0	0	0	0	1	0	0	3	0	2	1	0	0	C44
SCC of skin	111	0	1	0	0	0	0	0	0	0	1	2	2	4	6	14	27	15	16	23	C44
BCC	259	0	0	0	0	0	1	2	3	4	9	11	15	26	40	25	33	21	20	49	C44
Mesothelioma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	1	C45
Kaposi Sarcoma	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0	C46
Connective tissue	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	C49
Breast	231	0	0	0	0	0	0	2	7	9	15	20	22	26	31	32	21	12	8	26	C50
Vulva	4	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	0	0	0	C51
Vagina	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	C52

Cervix	46	0	0	0	0	0	0	0	2	6	1	4	6	8	6	5	3	1	1	3	C53
Uterus	20	0	0	0	0	0	0	0	0	1	0	0	2	4	3	3	4	2	0	1	C54
Ovary	19	0	0	0	0	0	1	0	0	0	0	0	1	2	1	7	2	1	1	3	C56
Other specified	11	0	0	0	0	0	0	0	0	0	2	0	0	1	5	0	1	0	0	2	C63
Kidney	8	0	0	1	0	0	0	0	0	0	0	0	0	2	2	1	1	0	0	1	C64
Bladder	13	0	0	0	0	0	0	0	0	0	0	0	0	3	1	2	3	1	0	3	C67
Brain, CNS	16	1	0	0	0	0	0	0	0	0	1	0	2	4	1	3	1	2	1	2	C71
Thyroid	12	0	0	0	0	0	1	1	0	1	3	1	1	0	0	2	0	0	0	2	C73
Endocrine	5	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	2	C74
Ill defined	3	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	1	C76
Primary site unknown	34	0	0	0	0	0	0	1	2	0	2	2	1	3	7	6	3	0	1	6	C80
Hodgkin lymphoma	5	0	0	0	0	0	1	0	1	0	0	0	0	1	0	1	0	0	0	1	C81
Non Hodgkin lymphoma	25	0	1	0	0	0	0	0	1	0	2	1	3	3	4	5	1	2	1	1	C84
Myeloma	8	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2	1	3	C90
Leukaemia	8	0	1	0	0	0	0	0	0	0	0	0	1	2	0	1	0	2	1	0	C92
Haematology other	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	C96

ALL MALES																					
Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	2245	2	15	9	13	18	16	21	31	80	86	137	189	267	318	341	217	122	76	294	ALL
All sites but C44	1540	2	15	9	12	18	16	19	27	61	54	100	129	188	245	240	129	65	37	181	ALLbC44
Lip	6	0	0	0	0	0	0	1	0	0	1	1	1	0	1	0	0	0	0	1	C00
Tongue	14	0	0	0	0	0	0	0	0	0	1	0	2	3	4	3	1	0	0	0	C02
Mouth	14	0	0	0	0	0	0	1	0	0	0	4	1	0	4	2	0	0	0	2	C06
Salivary gland	7	0	0	0	0	0	0	0	0	1	0	1	0	1	0	3	0	0	0	1	C07
Naso-Oropharynx	27	0	0	0	0	0	1	1	0	1	0	2	3	6	5	2	3	0	0	3	C11
Oesophagus	65	0	0	0	0	0	0	0	0	0	0	5	6	9	16	16	5	1	2	5	C15
Stomach	27	0	0	0	0	0	0	0	0	3	0	2	4	5	4	2	2	0	2	3	C16
Small intestine	6	0	0	0	0	0	0	0	0	0	2	0	0	3	0	0	0	0	0	1	C17
Colorectal	121	1	0	0	0	0	1	1	1	5	4	9	16	14	22	16	10	12	3	8	C18
Anus	15	0	0	0	0	0	0	0	1	1	2	5	1	0	1	3	0	0	0	1	C21
Liver & Bile duct	32	0	0	0	0	0	0	1	2	1	3	1	3	6	4	5	2	1	1	2	C22
Pancreas	28	0	0	0	0	0	0	0	0	1	1	0	5	3	4	7	1	3	0	3	C25
Larynx	16	0	0	0	0	0	0	0	1	0	0	1	2	3	5	1	0	0	0	3	C32
Lung	82	0	0	0	0	0	0	0	2	1	4	2	6	11	13	16	9	5	2	11	C34
Bone	15	0	0	0	1	1	1	1	1	1	2	1	1	0	2	2	0	0	0	1	C41
Melanoma	73	0	0	0	0	0	1	0	2	3	2	5	2	6	14	8	10	7	5	8	C43
BCC	489	0	0	0	0	0	0	1	3	14	21	23	44	62	61	78	54	31	22	75	C44
Skin other	25	0	0	0	0	0	0	0	0	4	4	3	2	2	2	2	3	2	0	1	C44
SCC of skin	191	0	0	0	1	0	0	1	1	1	7	11	14	15	10	21	31	24	17	37	C44
Mesothelioma	8	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	0	1	3	C45
Kaposi Sarcoma	40	0	1	0	0	1	2	2	6	6	2	7	2	3	0	2	2	0	0	4	C46
Connective tissue	21	0	1	1	0	0	1	1	0	1	3	1	5	1	2	2	1	0	0	1	C49
Breast	15	0	0	0	0	0	0	0	0	2	0	0	2	1	3	2	1	1	0	3	C50
Penis	9	0	0	0	0	0	0	0	0	0	3	3	1	0	1	0	1	0	0	0	C60
Prostate	476	0	0	0	0	0	1	0	0	1	3	13	27	66	100	97	51	20	14	83	C61

Testis	9	0	1	0	0	0	0	1	5	1	0	0	0	0	0	1	0	0	0	0	C62
Other specified	18	0	1	0	0	1	0	0	0	1	0	0	2	3	2	5	3	0	0	0	C63
Kidney	13	0	4	0	0	0	0	0	0	0	0	2	0	4	1	0	1	1	0	0	C64
Bladder	46	0	0	0	0	1	0	0	1	0	1	4	3	4	4	7	8	4	3	6	C67
Eye	9	0	2	0	0	0	0	1	0	2	0	0	2	1	1	0	0	0	0	0	C69
Brain, CNS	32	1	1	2	0	2	0	3	1	2	1	1	0	5	3	3	3	2	2	2	C71
Thyroid	6	0	0	0	0	0	0	0	0	1	0	1	0	1	2	1	0	0	0	0	C73
Endocrine	5	0	0	1	0	0	0	0	0	1	0	1	1	1	0	0	0	0	0	0	C74
Ill defined	13	0	0	0	0	0	0	0	0	2	1	1	1	1	3	4	0	0	0	0	C76
Primary site unknown	115	0	1	0	3	1	2	0	2	5	7	13	9	14	11	24	6	2	1	14	C80
Hodgkin lymphoma	34	0	0	2	5	4	2	4	0	5	0	3	4	0	2	1	1	0	0	1	C81
Burkitt lymphoma	2	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	C83
Non Hodgkin lymphoma	66	0	1	2	1	7	1	0	1	9	5	6	8	6	5	3	1	3	1	6	C84
Myeloma	23	0	0	0	0	0	0	0	0	1	1	1	2	4	3	1	2	3	0	5	C90
Leukaemia	27	0	2	1	1	0	1	1	1	1	2	4	5	3	2	0	3	0	0	0	C92
Haematology other	5	0	0	0	0	0	1	0	0	0	2	0	1	0	1	0	0	0	0	0	C96

ASIAN MALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	28	0	0	0	1	0	0	1	1	3	1	1	2	3	3	6	3	0	0	3	ALL
All sites but C44	25	0	0	0	1	0	0	1	1	2	1	1	2	3	3	5	3	0	0	2	ALLbC44
Lip	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	C00
Mouth	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	C06
Naso-Oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C11
Oesophagus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C15
Colorectal	3	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	C18
Liver & Bile duct	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C22
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C25
Lung	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C34
Melanoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C43
SCC of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	C44
BCC	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	C44
Prostate	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	2	C61
Testis	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	C62
Kidney	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C64
Endocrine	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	C74
Primary site unknown	4	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	C80
Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	C81
Non Hodgkin lymphoma	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C84

BLACK MALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	831	0	14	8	9	13	14	15	20	50	53	60	86	110	132	112	42	14	12	70	ALL
All sites but C44	753	0	14	8	8	13	14	14	19	44	41	53	77	102	123	101	39	13	12	61	ALLbC44
Tongue	6	0	0	0	0	0	0	0	0	0	0	0	2	2	0	1	1	0	0	0	C02
Mouth	8	0	0	0	0	0	0	0	0	0	0	2	0	0	3	2	0	0	0	1	C06
Salivary gland	4	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1	0	0	0	0	C07
Naso-Oropharynx	17	0	0	0	0	0	1	0	0	1	0	2	3	4	3	1	1	0	0	1	C11
Oesophagus	36	0	0	0	0	0	0	0	0	0	0	3	4	5	8	11	1	1	2	1	C15
Stomach	15	0	0	0	0	0	0	0	0	3	0	0	3	4	3	0	0	0	0	2	C16
Small intestine	5	0	0	0	0	0	0	0	0	0	2	0	0	3	0	0	0	0	0	0	C17
Colorectal	40	0	0	0	0	0	1	1	0	1	3	4	6	5	5	7	2	3	1	1	C18
Anus	13	0	0	0	0	0	0	0	1	1	2	5	1	0	1	2	0	0	0	0	C21
Liver & Bile duct	16	0	0	0	0	0	0	1	2	1	3	0	2	2	2	2	0	0	0	1	C22
Pancreas	8	0	0	0	0	0	0	0	0	0	0	0	2	1	1	3	0	1	0	0	C25
Larynx	15	0	0	0	0	0	0	0	1	0	0	1	1	3	5	1	0	0	0	3	C32
Lung	25	0	0	0	0	0	0	0	2	1	4	0	3	3	6	3	1	1	0	1	C34
Bone	10	0	0	0	0	1	1	1	1	1	1	1	0	0	1	2	0	0	0	0	C41
Melanoma	9	0	0	0	0	0	0	0	0	1	1	0	0	0	3	1	1	1	1	0	C43
Skin other	12	0	0	0	0	0	0	0	0	4	2	2	1	0	1	1	1	0	0	0	C44
BCC	40	0	0	0	0	0	0	0	0	1	6	2	4	4	8	8	0	1	0	6	C44
SCC of skin	26	0	0	0	1	0	0	1	1	1	4	3	4	4	0	2	2	0	0	3	C44
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	C45
Kaposi Sarcoma	36	0	1	0	0	1	2	2	6	5	2	5	2	3	0	2	1	0	0	4	C46
Connective tissue	14	0	1	1	0	0	1	1	0	0	2	1	4	1	0	1	0	0	0	1	C49
Breast	6	0	0	0	0	0	0	0	0	1	0	0	2	0	2	0	0	0	0	1	C50
Penis	8	0	0	0	0	0	0	0	0	0	3	3	1	0	1	0	0	0	0	0	C60
Prostate	231	0	0	0	0	0	1	0	0	1	0	4	12	44	54	44	25	5	7	34	C61
Testis	3	0	1	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	C62

Other specified	8	0	1	0	0	0	0	0	0	1	0	0	1	1	2	1	1	0	0	0	C63
Kidney	5	0	3	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	C64
Bladder	7	0	0	0	0	1	0	0	1	0	1	0	0	1	1	1	0	1	0	0	C67
Eye	9	0	2	0	0	0	0	1	0	2	0	0	2	1	1	0	0	0	0	0	C69
Brain, CNS	8	0	1	2	0	1	0	2	0	1	0	0	0	0	0	0	0	0	0	1	C71
Thyroid	4	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0	0	0	0	C73
Endocrine	2	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C74
Ill defined	11	0	0	0	0	0	0	0	0	2	1	1	1	1	3	2	0	0	0	0	C76
Primary site unknown	69	0	1	0	3	1	2	0	2	5	7	8	9	7	8	9	3	0	1	3	C80
Hodgkin lymphoma	27	0	0	2	4	2	2	4	0	3	0	3	3	0	2	1	0	0	0	1	C81
Burkitt lymphoma	2	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	C83
Non Hodgkin lymphoma	42	0	1	1	0	6	1	0	1	8	5	4	5	3	3	1	0	0	0	3	C84
Myeloma	9	0	0	0	0	0	0	0	0	1	1	1	2	3	0	0	0	0	0	1	C90
Leukaemia	20	0	2	1	0	0	0	1	1	1	1	4	4	2	2	0	1	0	0	0	C92
Haematology other	3	0	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	C96

COLOURED MALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	30	0	0	0	0	1	0	0	1	1	1	3	1	6	8	5	2	0	0	1	ALL
All sites but C44	27	0	0	0	0	1	0	0	1	1	1	3	1	6	7	4	2	0	0	0	ALLbC44
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C02
Oesophagus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C15
Stomach	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C16
Colorectal	6	0	0	0	0	0	0	0	0	0	0	2	1	1	2	0	0	0	0	0	C18
Pancreas	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	C25
Melanoma	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	C43
BCC	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	C44
Kaposi Sarcoma	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	C46
Prostate	4	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	0	0	0	C61
Other specified	2	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C63
Bladder	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C67
Primary site unknown	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	C80
Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	C81
Non Hodgkin lymphoma	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	C84
Haematology other	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	C96

WHITE MALES

Site	All Ages	Unknown Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	ICD10
All sites	1356	2	1	1	3	4	2	5	9	26	31	73	100	148	175	218	170	108	64	220	ALL
All sites but C44	735	2	1	1	3	4	2	4	6	14	11	43	49	77	112	130	85	52	25	118	ALLbC44
Lip	5	0	0	0	0	0	0	1	0	0	0	1	1	0	1	0	0	0	0	1	C00
Tongue	7	0	0	0	0	0	0	0	0	0	1	0	0	1	3	2	0	0	0	0	C02
Mouth	5	0	0	0	0	0	0	1	0	0	0	1	1	0	1	0	0	0	0	1	C06
Salivary gland	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	C07
Naso-Oropharynx	9	0	0	0	0	0	0	1	0	0	0	0	0	2	2	0	2	0	0	2	C11
Oesophagus	27	0	0	0	0	0	0	0	0	0	0	2	2	4	7	5	3	0	0	4	C15
Stomach	11	0	0	0	0	0	0	0	0	0	0	2	1	1	0	2	2	0	2	1	C16
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	C17
Colorectal	72	1	0	0	0	0	0	0	0	4	1	3	9	7	14	9	8	9	2	7	C18
Anus	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	C21
Liver & Bile duct	15	0	0	0	0	0	0	0	0	0	0	1	0	4	2	3	2	1	1	1	C22
Pancreas	17	0	0	0	0	0	0	0	0	1	1	0	2	0	3	4	1	2	0	3	C25
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C32
Lung	56	0	0	0	0	0	0	0	0	0	0	2	3	8	7	12	8	4	2	10	C34
Bone	5	0	0	0	1	0	0	0	0	0	1	0	1	0	1	0	0	0	0	1	C41
Melanoma	62	0	0	0	0	0	1	0	1	2	1	5	2	6	11	7	8	6	4	8	C43
Skin other	13	0	0	0	0	0	0	0	0	0	2	1	1	2	1	1	2	2	0	1	C44
BCC	444	0	0	0	0	0	0	1	3	12	15	21	40	58	52	68	54	30	22	68	C44
SCC of skin	164	0	0	0	0	0	0	0	0	0	3	8	10	11	10	19	29	24	17	33	C44
Mesothelioma	6	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	2	C45
Kaposi Sarcoma	3	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	C46
Connective tissue	7	0	0	0	0	0	0	0	0	1	1	0	1	0	2	1	1	0	0	0	C49
Breast	9	0	0	0	0	0	0	0	0	1	0	0	0	1	1	2	1	1	0	2	C50
Penis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C60
Prostate	236	0	0	0	0	0	0	0	0	0	3	9	15	21	43	51	25	15	7	47	C61

Testis	5	0	0	0	0	0	0	0	4	1	0	0	0	0	0	0	0	0	0	C62
Other specified	8	0	0	0	0	0	0	0	0	0	0	0	1	2	0	3	2	0	0	C63
Kidney	7	0	1	0	0	0	0	0	0	0	0	2	0	2	0	0	1	1	0	C64
Bladder	38	0	0	0	0	0	0	0	0	0	0	4	3	3	3	5	8	3	3	C67
Brain, CNS	24	1	0	0	0	1	0	1	1	1	1	1	0	5	3	3	3	2	2	C71
Thyroid	2	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	C73
Endocrine	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	C74
Ill defined	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	C76
Primary site unknown	39	0	0	0	0	0	0	0	0	0	0	5	0	5	2	12	2	2	0	C80
Hodgkin lymphoma	5	0	0	0	1	2	0	0	0	0	0	0	1	0	0	0	1	0	0	C81
Non Hodgkin lymphoma	21	0	0	1	0	1	0	0	0	1	0	2	3	2	2	2	0	3	1	C84
Myeloma	14	0	0	0	0	0	0	0	0	0	0	0	0	1	3	1	2	3	0	C90
Leukaemia	7	0	0	0	1	0	1	0	0	0	1	0	1	1	0	0	2	0	0	C92
Haematology other	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C96